From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review

Guillermo Valdivia¹,², Ángela Alonso-Diez¹,², Dolores Pérez-Alenza¹,² and Laura Peña¹,²*

¹Department Animal Medicine, Surgery and Pathology, Veterinary School, Complutense University of Madrid, Madrid, Spain, ²Mammary Oncology Unit, Complutense Veterinary Teaching Hospital, Complutense University of Madrid, Madrid, Spain

Canine mammary tumors (CMTs) are the most common neoplasm in intact female dogs. Canine mammary cancer (CMC) represents 50% of CMTs, and besides surgery, which is the elective treatment, additional targeted and non-targeted therapies could offer benefits in terms of survival to these patients. Also, CMC is considered a good spontaneous intermediate animal model for the research of human breast cancer (HBC), and therefore, the study of new treatments for CMC is a promising field in comparative oncology. Dogs with CMC have a comparable disease, an intact immune system, and a much shorter life span, which allows the achievement of results in a relatively short time. Besides conventional chemotherapy, innovative therapies have a large niche of opportunities. In this article, a comprehensive review of the current research in adjuvant therapies for CMC is conducted to gather available information and evaluate the perspectives. Firstly, updates are provided on the clinical–pathological approach and the use of conventional therapies, to delve later into precision therapies against therapeutic targets such as hormone receptors, tyrosine kinase receptors, p53 tumor suppressor gene, cyclooxygenases, the signaling pathways involved in epithelial–mesenchymal transition, and immunotherapy in different approaches. A comparison of the different investigations on targeted therapies in HBC is also carried out. In the last years, the increasing number of basic research studies of new promising therapeutic agents on CMC cell lines and CMC mouse xenografts is outstanding. As the main conclusion of this review, the lack of effort to bring the in vitro studies into the field of applied clinical research emerges. There is a great need for well-planned large prospective randomized clinical trials in dogs with CMC to obtain valid results for both species, humans and dogs, on the use of new therapies. Following the One Health concept, human and veterinary oncology will have to join forces to take advantage of both the economic and technological resources that are invested in HBC research, together with the innumerable advantages of dogs with CMC as a spontaneous animal model.

Keywords: canine mammary cancer, targeted therapy, markers, immunotherapy, immunophenotyping, hormonal therapy, tyrosine kinase receptors inhibitors
INTRODUCTION

Canine mammary tumors (CMTs) are a highly heterogeneous group of neoplasms that represent between 50 and 70% of all tumors in intact female dogs (1–4). The prevalence varies depending on the geographic location, being greater in countries where ovariectomy is not routinely performed (4). In these countries, the prevalence of mammary neoplasms in female dogs is three times higher than the prevalence in women (3). Historically, roughly 50% of CMTs are considered to be malignant (1, 2, 5, 6). However, recent studies have shown an increase in malignant vs. benign tumors over the last years, a similar trend that has been detected in human medicine (2).

Canine mammary cancer (CMC) and human breast cancer (HBC) share not only the aforesaid trend but also many epidemiological, environmental, biological, clinical, genetic, and pathological features, including a remarkable histological and molecular heterogeneity. Many authors have claimed CMC as a good spontaneous model for the study of HBC, especially the inflammatory mammary cancer, the deadliest type (7–12).

In female dogs and in women, mammary cancer is the most frequently diagnosed malignancy (4) and the leading cause of cancer-related death in women worldwide (13). For this reason, over the past two decades, innovative HBC treatments have incredibly evolved to place emphasis on more molecularly directed individual therapies while diminishing radio- and chemotherapy to reduce the adverse effects of treatment (14).

Since the publication of the intrinsic molecular classification of Perou and Solie in 2000, which distinguished four subtypes of HBC (luminal A, luminal B, basal-like, and HER-2 enriched), the clinical management shifted to a biology-centered approach, based on the expressions of estrogen and progesterone receptors (luminal subtypes), the human epidermal growth factor receptor 2 (HER-2), and basal markers (positive for high-molecular-weight cytokeratins, as cytokeratins 5/6, 14, and 17) (15). Nowadays, the classification of five molecular subtypes (luminal A, luminal B HER-2−, luminal B HER-2+, HER-2 enriched, and triple negative) is the most widely utilized in human medicine to elect targeted therapy: anti-estrogenic drugs for the luminal subtypes and anti-HER-2 treatment for the HER-2-enriched tumors. Unfortunately, since triple-negative mammary cancer does not currently have a specific targeted therapy, its prognosis is poor (14). Surgery is the treatment of choice in both HBC and CMC, and adjuvant therapies are only given on a routine basis in HBC. On the contrary to HBC treatment, adjuvant chemotherapy has not been proven to have a clear benefit in dogs with CMC yet (16–19). In spite that the application of clinical staging of patients with CMC and the histological grading of the neoplasms have helped to standardize prognosis and treatments, no precision therapies are routinely administered to dogs bearing mammary neoplasms. For all these reasons, the CMC-related mortality is relatively high: over 40% of the patients die within a year after diagnosis (20). There is an urge to developing updated therapeutic protocols and targeted therapies. Therefore, a comprehensive review of the current research in adjuvant therapies for CMC is conducted here to gather available information and evaluate the perspectives.

CONVENTIONAL AND NEW CLINICAL AND HISTOLOGICAL APPROACHES

Staging System

Dogs with CMC are staged according to the modified World Health Organization (WHO) TNM system (T, size of tumor; N, affection of lymph nodes; M, distant metastasis) (21).

More recently, a pathological staging system inspired in human oncology, in which T is replaced by pathologic tumor size (pT) and N is replaced by the pathologic nodal status (pN), with the addition of lymphovascular invasion (LVI) has been proposed, the stages being 0, I, II, IIIA, and IIIB (22). The use of this system is still limited, the major criticism being its inability to discriminate different stages of malignancy in cases with no LVI or lymph node affection, which are the vast majority.

The current staging system is not flexible enough to allow prognostic differences between specific tumor types and subtypes and does not consider tumor grades or lymphovascular invasion (21). Therefore, new “bio-score” systems combining the anatomical staging (TNM) with many histological and biological variables have been developed: multivariate scoring (scores from 0 to 40) and refined flexible scoring (scores from 0 to 6.5). Although both systems were accurate in predicting the survival, the refined flexible scoring was superior in differentiating dogs with a high or a low risk of metastasis (23). Greater efforts should be made to implement these bio-score systems in larger prospective studies, allowing for more widespread use and the refinement of these increasingly accurate prognostic systems.

Histopathological Classification and Grading

The new classification of CMTs (24), which substitutes the WHO’s 1974 and the last 2011 classification (5), together with the current grading system used worldwide for malignant CMC (9), as an adaptation of the Nottingham method utilized for HBC (25), have given tools to pathologists for accurate diagnosis and prognosis of CMTs since several studies have validated the prognostic significance of histopathological classification and grading (26, 27).

Cell Markers for Diagnosis: Immunophenotyping

Normal mammary gland cells of both humans and dogs have distinct immunoprofiles that can be used for diagnosis and potentially for targeted therapies. Luminal epithelial cells are characterized by the expression of low-molecular-weight (LMW) type I acidic cytokeratins (CKs) 18 and 19 and type II basic CKs 7 and 8. Basal/myoepithelial cells express high-molecular-weight (HMW) type I acidic CKs 14 and 17 and type II basic CKs 5 and 6 (Figures 1, 2). Myoepithelial cells, much more proliferative in CMC than in HBC (5), also express other markers such as p63, vimentin, calponin, smooth muscle actin (SMA), P-cadherin, CD10, epidermal growth factor receptor (EGFR), maspin, and 14-3-3 sigma protein (28–31) (Figures 3–5). However, a study performed in 2014 showed that, as happens in human breast
The mammary gland subpopulations are more complex than this. Using single and double immunohistochemistry (IHC) on serial sections of normal canine mammary gland, five distinct subpopulations were identified: (1) progenitor cells (CK5+, CK14+, p63+, and VIM+); (2) intermediary myoepithelial cells (CK5+, CK14+, p63+, SMA+, CALP+, and VIM+); (3) terminally differentiated myoepithelial cells (CALP+, SMA+, and VIM+); (4) intermediary luminal glandular cells (CK5+, CK14+, and CK8/CK18+); and (5) terminally differentiated luminal glandular cells (CK8/CK18+). The ducts are considered regenerative niches as they contain progenitor cells and intermediary luminal glandular cells; however, these are located in the basal position (33) and not in the luminal position, as occurs in women (34).

Molecular Classification
In human breast pathology, IHC is routinely used to assist with the diagnosis and to determine the specific treatment for patients (35). Over the past years, there has been considerable efforts to characterize and classify HBC at the molecular level to establish effective individual treatments. However, due to time and cost constraints, the surrogate molecular breast cancer classification is still largely based on IHC assessment of biomarkers: estrogen receptor (ER), progesterone receptor (PR), HER-2, and Ki-67, among others (36). Nowadays, HBC is classified on the following molecular subtypes by IHC (Table 1): luminal A (ER/PR+, HER-2–, and Ki-67 low), luminal B HER-2 negative (ER+, PR– or low, HER-2–, and Ki-67 high), luminal B HER-2 positive (ER+, PR+/–, HER-2+, and Ki-67 high), HER-2 enriched or overexpressed (ER/PR–, HER-2+, and Ki-67 high), and triple negative (ER–, PR–, HER-2–, and Ki-67 high). Triple-negative breast cancer (TNBC) can be further subdivided, according to genetic signatures, into luminal androgen receptor (LAR), mesenchymal (MES), and two basal-like subtypes (positive for high-molecular-weight cytokeratins): immunosuppressed (basal-like immunosuppressed, BLIS) and immune-activated (basal-like immune-activated, BLIA), depending on the upregulation or downregulation of genes associated with T, B, and natural killer (NK) cells (14, 36, 37).

Despite the relevance of molecular subtyping in HBC, highly variable and even contradictory results have been obtained in CMC (10, 38–43). Regardless of the established guidelines for...
immunohistochemical assessment (31), variable application of the criteria has been utilized, and the percentages of the molecular subtypes differ enormously among investigations.

HER-2 immunodetection in CMTs has always remained controversial. In a study performed by Abadie et al. (10), following appropriate standardized intrinsic and extrinsic controls (31), there were no HER-2-enriched tumors, in contrast to other studies in which between 5 and 15% of the mammary neoplasms were classified as HER-2 enriched (38, 42, 43). Previous studies identified HER-2 in normal, hyperplastic, and dysplastic mammary tissues and found no relation with prognostic parameters such as disease-free interval (DFI), overall survival (OS), and lymphovascular invasion, suggesting that HER-2 may play a role in the proliferation of mammary tissue in female dogs, but not conclusively in its malignant transformation (40). Furthermore, in a recent publication (44), HER-2 messenger RNA (mRNA) expression was observed in neoplastic and non-neoplastic mammary tissues using a novel quantitative RNA in situ hybridization assay, which correlates with the immunohistochemistry score. Among the non-neoplastic mammary tissues (hyperplasia), all cases showed HER-2: 21.4% were classified as 1+, while 78.6% were positive (2+ and 3+) (Figure 6). Moreover, within neoplastic tissues, no significant associations between HER-2 expression and clinical parameters were found.

The specificity of human anti-HER-2 antibody (Dako A0485) for HER-2 immunolabeling in canine tissues is also controversial. While one study showed no evidence of its specificity in canine tissues by Western blotting and subsequent mass spectrometric analysis (45), another work showed the cross-reactivity of the human anti-HER2 antibody in canine tissue (urothelial) by Western blotting (46).

Triple-negative tumors account for approximately half of CMCs (58.6%) (10), and showed significantly shorter disease-free interval (DFI) and overall survival (OS) in comparison to luminal A tumors. Comparable results were obtained in other studies: a triple-negative phenotype was related to a higher histological grade of malignancy, lymphatic invasion, and poorer prognosis. On the other hand, luminal A tumors were frequently complex tumors associated with better prognosis and longer DFI and OS (10, 38, 42, 43). In a study, HER-2-enriched and triple-negative CMCs presented a downregulation of E-cadherin compared to the luminal A and B subtypes, which are related to invasion and metastasis (43).
Surgery
Surgery is the primary treatment in the control of CMTs; the goal is to remove the tumor(s) with clean margins and, depending on the case, to prevent the development of new tumors in the remaining glands (4). Clean margins have been found to be predictive of the median survival time (MST) in dogs with stages I–III (19), and very recent publications have elucidated new strategies for the intraoperative assessment of margins using near-infrared light waves to generate real-time, high-resolution images on the microscopic scale, similar to low-power histopathology (47–49).

Despite the elevated frequency of CMTs, there is a lack of prospective clinical trials robust enough to establish the extent of surgical excision: simple lumpectomy, local mastectomy, regional mastectomy, total chain mastectomy, or bilateral total mastectomy (4). Nevertheless, the current literature recommendations are the following: If a single, small (<1 cm) tumor is present, nodulectomy is usually carried out. Simple mastectomy is indicated when the tumor is larger and centrally located within the mammary gland. When multiple tumors are in consecutive glands, or a single tumor is found between two mammary glands, regional mastectomy (excision of adjacent mammary glands, from one to two or from three to five) is performed. Finally, total mastectomy is indicated when multiple tumors are distributed throughout the mammary chain, regardless of the size (4). Those cases in which surgery is not recommended are advanced metastatic (stage V) cancer (17, 50) and inflammatory mammary cancer (IMC) (7, 8, 51).

Additional treatment (adjuvant therapy) can be given after the primary mammary cancer treatment (surgery) to lower the risk of developing further recurrences and metastasis. Adjuvant therapy may include chemotherapy, radiotherapy, and targeted or individualized therapy, this latest based on the specific genetic characteristics of the cancer in a patient (52–55).

Chemotherapy
Approximately 50% of the dogs with CMTs have at least a malignant neoplasm, and these patients would further profit from adjuvant chemotherapy. However, it has not been demonstrated conclusively if adjuvant chemotherapy offers a significant benefit to dogs with CMTs. Although cases have reported measurable tumor responses to doxorubicin (56–58), carboplatin (59, 60), mitoxantrone, and paclitaxel (61, 62), larger studies have not found a significant improvement of the measurable
clinical responses (MST, DFI, or OS) using gemcitabine (17), doxorubicin, docetaxel (16, 19), and mitoxantrone (19). Due to the lack of efficient chemotherapeutics, dogs with malignant CMTs show high rates of recurrence (63) and poor prognosis (64).

Despite this uncertainty, chemotherapy is frequently used in those dogs with tumors considered at high risk of metastasis or recurrence (4).

Another chemotherapeutic approach is oral metronomic chemotherapy, which involves the administration of the lowest biologically effective dose at frequent regular intervals (65). In veterinary medicine, metronomic chemotherapy has been studied since 2007 (66) in tumors that include hemangiosarcoma (67–72), osteosarcoma (73–76), hepatic neuroendocrine carcinoma (77), primary lung carcinoma (78), soft tissue sarcomas (79–82), and transitional cell carcinomas (83), with chemotherapeutics such as cyclophosphamide, lomustine, and chlorambucil. To date, only one study has been published regarding CMC (84), in which longer MSTs were observed in patients treated with surgery and metronomic chemotherapy compared to dogs treated with surgery and conventional chemotherapy.

Radiotherapy
Although radiotherapy is commonly used in HBCs with locoregional treatment (14), only one study has been published in CMC, specifically in dogs bearing IMC. Radiotherapy, in combination with piroxicam, toceranib, and thalidomide, showed significantly longer time to progression than those patients treated with the same regimen, but without radiotherapy (85).

ADJUVANT TARGETED THERAPIES
Targeted therapies involve drugs that block the growth of cancer by interfering with individually expressed specific molecules responsible for tumor cell proliferation, survival, metastasis, or microenvironment (86). Given the poorly efficient available adjuvant therapies in dogs with mammary cancer, several studies have been made in vitro in animal models (mice) and few clinical trials, which are shown below.

Hormonal Therapy
Estrogens, progesterone, prolactin (PRL), and growth hormone (GH) are essential for physiological mammary development. The
FIGURE 5 | Carcinoma and malignant myoepitheloma, mammary gland, dog. Immunohistochemical nuclear staining of p63. Interstitial proliferated myoepithelial cells are positive.

TABLE 1 | Classification of molecular subtypes in human breast cancer.

| Molecular subtypes | ER   | PR   | HER-2 | Ki-67 | HGM   |
|--------------------|------|------|-------|-------|-------|
| Luminal A          | +++  | +++  | –     | Low   | Low   |
| Luminal B HER-2 negative | +    | +/-  | –     | High  | Medium/high |
| Luminal B HER-2 positive | +    | +/-  | +/+   | High  | Medium/high |
| HER-2 enriched     | –    | –    | +++   | High  | High  |
| Triple-negative    | –    | –    | –     | High  | High  |

ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; HGM, histological grade of malignancy; LAR, luminal androgen receptor; MES, mesenchymal; BLIS, basal-like immunosuppressed; BLIA, basal-like immune-activated; AR, androgen receptor; MUC-1, cell surface-associated mucin-1; EMT, epithelial-mesenchymal transition; PDGFRα, platelet-derived growth factor receptor α; c-Kit, stem cell factor receptor; HMWCK, high-molecular-weight cytokeratins; VTCN1, immunosuppressive V-set domain-containing T cell activation inhibitor 1; STAT, signal transducer and activator of transcription gene family.

The effects of these hormones are mediated through binding to their respective receptors within the mammary gland (6) (Figures 7, 8). Estrogens and progesterone have been historically known to have a main role in tumorigenesis in CMTs, as spaying of female dogs before the first or second heat has significant protective effects (87). On the other hand, exposure to exogenous hormones (both estrogens and progestins) increases the risk of developing CMTs in dogs (88). Furthermore, studies have found that dogs with CMC have higher levels of estrogens in the blood, except in IMC, where the serum estrogens levels are lower than
in dogs with other malignant mammary tumors (89, 90). On the other hand, ER, PR, PRL, PRL receptor, and GH receptor have been found to be downregulated in malignant mammary tumors compared to normal mammary gland (91, 92) and benign tumors (92–94). Furthermore, lymphatic invasion, high mitotic index, large tumor size, and tumor grade are significantly associated with low ER/PR expressions. Tumors with low ER/PR expressions have poorer prognosis (89, 93, 94).

In human medicine, ER+ breast cancer is the most common subgroup (>70%) (95). The risk of ER+ breast cancer increases with exposure to estrogens during a lifetime, for example due to an earlier menarche or late menopause (14). Moreover, hormone replacement therapy on menopausal women increases the risk of breast cancer (96). In women with HBC, ER+ tumors are susceptible to anti-hormone treatment. This therapy is designed to target mainly ER using antiestrogens, such as tamoxifen or fulvestrant, or by inhibiting the endogenous synthesis of 17β-estradiol using aromatase inhibitors (97).

Tamoxifen is a selective inhibitor of ER that is widely utilized in the treatment of HBC. However, in dogs, severe adverse effects (vulvar edema, vaginal purulent discharge, and pyometra) are repeatedly seen, and that outweighs the possible benefits of this hormone therapy (98, 99).

For this reason, other antiestrogens are being studied for their use in CMC. Indole-3-carbinol is a natural phytochemical found in cruciferous vegetables (i.e., cauliflower, cabbage, and broccoli) that has been proven to suppress cell proliferation and induce apoptosis in breast cancer cell lines by multiple mechanisms such as blocking estrogen receptors (100, 101). In veterinary medicine, a mouse xenograft model of canine IMC was treated with indole-3-carbinol, resulting in decreased tumor proliferation and increased apoptosis, although metastasis and lymphatic embolization were not prevented (102).

When women reach menopause, the ovaries no longer produce estrogen; however, this hormone is produced at other sites (fat, liver, muscle, and mammary tissue) through the
Aromatase enzyme (103). Aromatase mRNA levels are higher in cancerous tissues than in normal breast tissues in humans (104). Therefore, while ER inhibitors (e.g., tamoxifen) are preferentially given in premenopausal women with ER+ HBC, aromatase inhibitors are used for the treatment of postmenopausal patients with ER+ breast cancer (103). In dogs, IMC has been shown to express higher levels of aromatase than non-IMC. Moreover, *in vitro* treatment with letrozole, an aromatase inhibitor, significantly reduced cell proliferation in an IMC cell line (105).

No clinical trials on the use of aromatase in dogs with CMC have been reported.

Melatonin is a hormone produced by the pineal gland in response to darkness, regulated by photoperiod (106). In breast tissue, melatonin exerts its action through two receptors: melatonin receptors 1 and 2 (MT1 and MT2, respectively) (107). A positive correlation between MT1 and ERα expressions has been demonstrated and recognized as a prognostic marker for OS in HBC (108). Furthermore, melatonin has been shown to suppress the proliferation of HBC cell lines *in vitro* and *in vivo* by disrupting estrogen-dependent signaling as well as inhibiting estrogen production in the gonads and in breast tissues through the aromatase pathway (109–111).

In the last decades, the role of androgens on HBC has started to gain the attention of researchers. Not only can androgens be a source of estrogen through the aromatase pathway but they have also been directly implicated as possible carcinogen factors for breast cancer (112). The androgen receptor (AR) is expressed in ∼70–90% of invasive human breast cancers, a frequency comparable to or higher than those reported for ER (70–80%) and PR (50–70%) (113, 114). On the other hand, AR has been found in 64% of IMC and 40% of non-inflammatory CMC (89) (Figure 9). To date, in human medicine, AR-targeted drugs have been approved for the treatment of prostate cancer, and different AR inhibitors are being investigated for the treatment of HBC, specifically for the LAR subtype of triple-negative breast cancer (115). Flutamide is an analog of androgen that blocks the AR (116). It is already used in veterinary medicine to treat canine prostate hyperplasia and cancer (117), but has not been tested in patients with CMC. Flutamide has been shown *in vitro* to decrease the proliferation of an IMC cell line, and reductions in...
the tumor size and metastasis rates in IMC xenografted mice were found (118).

Progesterone has also a relevant role in HBC (119) and in CMC (105, 120). Progesterone signals via PR, whose expression is stimulated by estrogen (121). Some authors have suggested that progesterone may lead the transition of tumors from luminal to a basal phenotype (122). Upon progesterone exposure, luminal cells secrete growth factors (RANKL and Wnt) that may stimulate the recruitment and differentiation of cancer stem cells (CSCs, characterized by CD40\textsuperscript{HIGH} and CD24\textsuperscript{LOW}) (123).

Therapeutic targeting of PRs have been studied in HBC as a treatment of endocrine refractory breast cancer, the most common drugs being megestrol acetate, medroxyprogesterone acetate, mifepristone, and onapristone (124). The antiprogestins aglepristone is employed in veterinary medicine for abortion, parturition induction, and pyometra treatment in female dogs (125). The study of antiprogestins in oncology has begun relatively recently. Mifepristone and onapristone have been shown to decrease the number of viable tumor cells in vitro in a canine mammary carcinoma cell line (126). In vivo, aglepristone treatment diminished the expression of PR, reduced the proliferation index in PR+ CMTs (127), and significantly increased DFI and OS in cases with PR+, <3 cm, low and medium grade, low proliferative tumors (128). Although promising for PR+ CMTs, antiprogestins in veterinary oncology need further studies with larger series and longer follow-up periods.

Oxytocin is a peptide hormone mainly synthesized in the hypothalamus that plays a role in uterine contraction and milk ejection, among other functions, and has been linked to the mammary carcinogenic process. Human (129) and canine (130) carcinoma cell lines and HBC xenografted mice (131) have shown reduced proliferation after oxytocin treatment. Recently, it has been shown that the expression of oxytocin receptors in CMTs is associated with ER+, benign tumors, and low-grade malignant tumors compared to high-grade malignant tumors (132).

Desmopressin is a synthetic analogous of vasopressin (antidiuretic hormone) that binds to the V2 membrane receptor (V2R); it has been used for the management of diabetes insipidus
in humans (133) and dogs (134). Since V2R is also expressed in endothelial cells, desmopressin has been employed in the treatment of different bleeding disorders due to its effects in the hemostatic system (135). In oncology, a number of studies have shown in mouse models of HBC and in different HBC cell lines that this peptide seems to have anti-metastatic and anti-proliferative effects, probably by targeting V2R-expressing cancer cells and raising intracellular cAMP (136, 137). In a study on canine mammary carcinoma cell lines, desmopressin was shown to decrease cell viability at high concentrations (130). Furthermore, a veterinary clinical trial has demonstrated that the perioperative administration of desmopressin increases the DFI and OS in CMC (138). Although it seemed a very promising therapy, there have been no subsequent clinical trials in veterinary or human medicine performed by this group, with the exception of a phase II trial in HBC patients in 2015 (139), where the safety of perioperative administration was established; however, the effect on DFI, OS, or any other clinical parameter has not been reported. Due to this controversy, Sorenmo et al. conducted a prospective randomized trial in dogs with CMC, in which no metastasis-preventing effect of desmopressin was found (140).

**Tyrosine Kinase Receptors**

Tyrosine kinase receptors (TKRs) catalyze a series of phosphorylation of target proteins that play a significant role in cell proliferation, metabolism, motility, survival, and apoptosis, as well as endothelial cell activation, leading to neovascularization.

Breakthroughs in biotechnology over the past decades have led to the development of new molecules that act on specific targets, among which small-molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) stand out. Small-molecule (below 900 Da) tyrosine kinase inhibitors rapidly diffuse across cell membranes and target intracellular or extracellular proteins (kinases). To identify TKIs, the suffix “nib” is placed at the end of the generic name (141). On the other hand, monoclonal antibodies cannot cross cell membranes, therefore acting on the extracellular targets. The stem “mab” at the end of the name corresponds to mAbs. When the monoclonal antibody is completely human, the “umab” substem is used (e.g., nivolumab). If the immunoglobulin is chimeric (human constant domain, plus non-human variable domain), the mAb is named with the “ximab” substem; when the antibody is humanized (human framework with grafted murine...
complementary determining regions), then the “zumab” substem is utilized (e.g., trastuzumab) (142).

Among TKRs, HER-2, vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), stem cell factor receptor (c-KitR), and colony-stimulating factor 1 (CSF-1) are overexpressed or constitutively activated in human and canine tumors (143, 144). Tyrosine kinase inhibitors act by competitive inhibition of ATP binding, thus avoiding consecutive phosphorylation reactions and blocking signal transduction to the nucleus, inducing the deregulation of cellular proliferation and differentiation (145). Most of the TKIs are given orally, which means a huge benefit for animal welfare, diminishing stressful situations and providing ease of administration by the owner (146). For these reasons, several attempts to block these receptors have been made in veterinary oncology. Some TKIs designed for human oncology can have multiple actions depending on the receptor blocked (i.e., sunitinib inhibits VEGFR, PDGFR, c-KitR, and CSF-2) (147) and can be served for different types of cancer. Below, we review these targets separately.

**Anti-Her-2**

The family of EGFRs encompasses four tyrosine kinases receptors also named human epidermal receptors (HERs): HER-1, HER-2, HER-3, and HER-4. When activated, these receptors trigger numerous signaling pathways, which regulate cell proliferation and survival, as well as the metastasis of tumor cells (144). Approximately 15–25% of HBC show overexpression of the HER-2 protein and/or amplification of the HER-2 gene, which is generally associated with a poor prognosis and an aggressive disease course (148).

The targeted therapy with anti-HER-2 agents in HBC is well-established. Several classes of anti-HER-2 agents have been developed, including: (1) monoclonal antibodies that bind to the extracellular domain of HER-2, such as trastuzumab and pertuzumab, which act by direct inhibition of HER-2 and indirect activation of the immune system to evoke antibody-dependent cellular toxicity; (2) small-molecule TKIs, including lapatinib, neratinib, and afatinib, that bind to the intracellular tyrosine kinase domains of HER-2 and other HER family members; and (3) antibody–drug conjugates, e.g., trastuzumab emtansine (T-DM1), composed of a monoclonal antibody directed at the extracellular domain of HER-2 linked to a cytotoxic agent. All of the latter have been approved by the European Medicines Agency (EMA) for clinical use in patients with HER-2+ HBC (149).

The amino acid homology values between canine and human EGFR-1 and HER-2 are reported to be 91 and 92%, respectively (150). In *silico* studies (research conducted by computer modeling or simulation) have shown that cetuximab (monoclonal antibody against EGFR-1) epitopes only differ by four amino acids in canines, while the trastuzumab (monoclonal antibody against HER-2) binding site is identical in humans and canines. In *vitro* studies with canine mammary carcinoma cells have reported a significant growth inhibition and G1/G0 phase arrest when treated with either cetuximab or trastuzumab (150). A "caninized" version of cetuximab developed by the same group, fusing the canine constant heavy-chain genes with the variable region murine genes of cetuximab, was able to inhibit the proliferation of canine mammary carcinoma cell lines, enhancing tumor cell killing via (151) phagocytosis.

With regard to anti-HER-2 TKIs, only gefitinib has been attested in CMTs. In *vitro* studies showed anti-proliferative effects in a canine mammary carcinoma cell line comparable to those with small interfering RNA (siRNA) targeting EGFR and HER-2 (152).

There are no clinical trials published on the use of HER-2 inhibitors in CMC, and their potential use in veterinary medicine is still far from daily routine.

**Anti-angiogenesis**

Since 1971, it is well-known that the growth of solid tumors, beyond the size of 1–2 mm³, is conditioned to a sufficient supply of nutrients and oxygen, for which the new development of blood vessels was hypothesized and called angiogenesis (153). In early tumor development, neoplastic cells are oxygenated through simple diffusion in a phase defined as “avascular state.” With time and growth, tumor cells are deprived of oxygen and undergo a phenotypical change into a pro-angiogenic state (angiogenic switch) by inducing specific gene expression to overcome hypoxia through sprouting angiogenesis, vasculogenic mimicry (VM), and/or vascular co-option (VCO) (154). The sprouting angiogenic process occurs in both normal and neoplastic tissues. It is a complex process regulated by pro- and anti-angiogenic factors, among which stands out the VEGF family receptors, especially VEGF-A and its receptor (VEGFR-2), the fibroblast growth factor receptor 2 (FGFR-2), and PDGFR (154). VM and VCO are only found in highly aggressive cancers, as is explained below.

In both, humans (155) and dogs (156), VEGF-2 and PDGFR are increased in malignant, triple-negative mammary tumors, being higher in those cases with metastatic disease (distant regional) and positively correlated with tumor grade. Further, in HBC, microvascular density (MVD) is significantly correlated with metastasis, OS, and DFI (157); likewise, MVD is increased in canine primary mammary tumors with distant metastasis (156, 158).

In human medicine, about one third of the molecular therapeutics in clinical development are directed against angiogenesis. Angiogenesis is mediated by two major molecular routes: the VEGF axis-dependent route and the non-VEGF-mediated mechanisms (159). The anti-angiogenic therapies against the VEGF family block either the ligands or the receptors (160). The most widely studied anti-angiogenic therapeutic is bevacizumab (monoclonal antibody against the anti-VEGF-A ligand). In 2008, it became the first Food and Drug Administration (FDA)-approved anti-angiogenic drug for HBC; however, due to the lack of significant clinical improvements in subsequent studies, the approval was revoked in 2011 (161).

Small-molecule TKIs that block the VEGF family receptors have also been developed (pazopanib, sunitinib, and sorafenib, among others), many of them not only acting against angiogenesis but also diminishing other tumor metabolic pathways (162). For instance, pazopanib acts as an anti-angiogenic through the inhibition of VEGFR, PDGFR, and c-Kit.
in human renal carcinoma, soft tissue sarcoma, and breast cancer in combination with the anti-HER-2 lapatinib (163). In addition, sunitinib, which inhibits VEGFR, PDGFR, c-KitR, and CSF-1R, has shown promising activity as a single agent for advanced HBC (164). On the other hand, sorafenib, a VEGFR, PDGFR, and rapid accelerated fibrosarcoma-1 (Raf-1) kinase inhibitor, has antitumor effects in vitro and inhibits neovascularization in xenograft models of HBC (165). Sorafenib has been assessed in veterinary medicine, and it has shown a promising ability to inhibit VM in CMC cell lines in vitro (166). Other TKIs that target VEGFR-2 and that have been proven to significantly diminish the level of active (phosphorylated) VEGFR2, reduce cell proliferation and migration, and increase apoptosis in in vitro studies against CMT cell lines are rivoceranib (apatinib) (167) and vandetanib (168).

Despite the logical targeting of angiogenic pathways in cancer treatment and significant efforts in new drug development and HBC clinical trials, no significant clinical benefit has been achieved that outweighs the potential side effects. Some authors have hypothesized that a multi-target approach to angiogenesis is needed to overcome the apparent resistance of tumors to anti-angiogenesis treatment (159).

As stated earlier, angiogenesis is not the exclusive method to nourish tumor cells; two other mechanisms have been discovered in highly aggressive neoplasms—VM (169, 170) and VCO (171)—which have been hypothesized as responsible for the resistance to anti-angiogenic therapy (172–174). VM describes the formation of de novo vascular channels lined by genetically deregulated highly malignant cancer cells (175). These cancer cells, also called endothelial-like cells, exhibit cancer stem cell markers and characteristic endothelial morphology under electron microscopy in cell lines of human and canine inflammatory mammary cancer (176). VM has been associated with the spread and metastasis of human (177) and canine mammary tumors (178). VM was found in 33% of canine mammary tumors, and its presence was correlated with histological grade of malignancy and shorter survival times (166).

In VCO, neoplastic cells closely adhere to preexisting blood vessels to obtain nutrients and oxygen and further develop sprouting angiogenesis after the hypoxia switch is turned on (174, 179). In veterinary medicine, VCO has not been recognized yet.

**Anti c-Kit and Other Receptors**
The stem cell factor receptor c-Kit is an active participant in many vital functions in humans and animals, such as homeostasis, cell maintenance, differentiation, and melanogenesis, in a wide variety of cells (180). However, overexpression or mutation where the receptor is constitutively activated has been detected in a number of tumors in humans (181) and dogs, notably in canine mast cell tumors (143). In canine mast cell tumors, the c-Kit receptor can be labeled by immunohistochemistry in three different staining patterns: pattern I (perimembranous staining), pattern II (focal or stippled cytoplasmic), and pattern III (diffuse cytoplasmic staining), pattern III being the more aggressive (182). In women, c-Kit is expressed in normal breast tissue and is gradually lost during the malignant progression of breast tumors due to a downregulation at the mRNA level (183). On the contrary, c-Kit has been found to be present in 38.5% of CMTs (184) (Figure 10) and seems to be overexpressed in malignant mammary tumors (185, 186), in addition to being correlated with the proliferation index (187) and angiogenesis (188).

In veterinary medicine, there are only two approved targeted anti-c-Kit TKIs: toceranib (Palladia) and masitinib. Toceranib, designed and approved for mast cell tumors in dogs, acts mostly through the inhibition of the c-KitR, and it is a sister compound to sunitinib, which was later approved for human therapies (189). Toceranib appears to exert antitumor activity against a variety of dog cancers, including CMC, particularly in cases with pulmonary metastases (143). Toceranib also has anti-angiogenic effects, inhibiting VEGF and PDGFR, and produces a significant decrease in regulatory T cells, which may increase immune surveillance (189). Toceranib has shown a discrete in vitro reduction in cell proliferation on canine mammary carcinoma cell lines (184).

The evaluation of toceranib in clinical trials with dogs with CMC is very limited. In a study with dogs presenting IMC, toceranib was given in combination with piroxicam (anti-COX-2) and thalidomide (an immunomodulatory and anti-angiogenic agent) (190), with or without hypofractionated radiation therapy. The authors found a significant improvement in the clinical benefit rate and overall survival time compared with historical palliative treatment. The response was better when radiotherapy was employed (85).

Masitinib is also a potent and selective inhibitor of the c-Kit receptor that has been recommended for its use in canine mast cell tumors (191). It also inhibits the PDGF receptor and the fibroblast growth factor receptor (FGFR-3). Masitinib has been studied in vitro as a “chemosensitizer” by enhancing the anti-proliferative effects of a cytotoxic drug, gemcitabine (192). There are no other studies on the treatment of CMC.

Although TKIs (in particular toceranib) are commonly used for CMC treatment, in the veterinary clinic, the evidence is merely anecdotal, and only the aforementioned studies, one in vitro (184) and two in vivo (85, 189), have been conducted. There is an urgent need for prospective randomized studies to adequately evaluate the effectiveness of toceranib in patients with CMC in c-Kit-positive or c-Kit-negative tumors.

Other tyrosine kinase inhibitors are under study. Palbociclib is an inhibitor of cyclin-dependent kinase 4 (CDK4) and CDK6, which are key regulators of the cell cycle machinery and, thus, cell proliferation (193). In women, palbociclib improves progression-free survival in ER+ HER-2- breast cancer when combined with an aromatase inhibitor (letrozole) or an ER downregulator (fulvestrant), so it received approval from the FDA and EMA (194). CDK6 has been consistently detected in CMT cells with no association to histotype or grade (64). In vitro studies with canine mammary cell lines have shown that palbociclib induces cell cycle arrest, prevents colony formation, and impairs cell migration activity (64). There are no clinical trials on dogs with CMC.

**Antitumor Suppressor Gene p53**
The tumor suppressor gene p53 plays a central role in tumorigenesis. The p53 protein, after tetramerization, inhibits cell proliferation, functioning as an initiator of cell cycle arrest...
and apoptosis. Mutations of \( p53 \) often cause a disruption of its tumor-suppressor function and induce genomic instabilities (195). Mutations in the \( p53 \) gene are associated with more than half of all human cancers and have been described in multiple cancers in dogs (196), including mammary tumors (197, 198). However, its expression and mutation status as prognostic factors in veterinary medicine are controversial: while some studies have found no correlation (199, 200), other authors have associated higher levels of \( p53 \) with poor overall survival (201, 202).

Mutation of the \( p53 \) gene can lead to a stable protein that is identifiable by immunohistochemistry (203), although a truncating mutation of the \( p53 \) gene can lead to an immunohistochemically undetectable protein (204). Therefore, four different patterns of \( p53 \) immunolabeling have been published: overexpression, complete absence, cytoplasmic staining, and wild-type staining. The first three patterns are related to an underlying \( p53 \) mutation, while the fourth pattern is primarily associated with no mutation (204, 205). Altered expressions of \( p53 \) may result from a direct mutation of \( p53 \) within tumor cells or from an altered localization of \( p53 \) by increased export of the protein from the nucleus, thereby decreasing its downstream targets and inhibiting apoptosis and cell cycle arrest (195).

Approximately 30% of HBCs have a \( p53 \) mutation, but this frequency is dependent on the molecular subtype, as the luminal subgroup has the lowest mutation rate and TNBC has the highest (up to 88%) (206). Additionally, \( p53 \) overexpression has been correlated with more aggressive HBCs and worst outcomes (207–209).

In CMC, malignant tumors have shown higher levels of \( p53 \) than benign tumors (210), and the increase of \( p53 \) is greater in higher-grade tumors with higher proliferation rates (211). Likewise, a significant correlation between increases in \( p53 \) expression and mutations with shorter OS has been found (212).

Since mutations in the \( p53 \) gene have an enormous impact on cancer development, great efforts are being made into the mechanisms that can counteract this effect and are brought together in several extensive reviews (213, 214) that compile different experimental approaches to target \( p53 \) in human cancer: inhibition of mutant \( p53 \) by promoting its protein degradation, restoration of the wildlife activity of mutant \( p53 \), and immune stimulation against \( p53 \) activity.

In contrast, there is only one study on \( p53 \) therapy in canine mammary cancer cells. Neoplastic cells can increase the cytoplasmic translocation of nuclear \( p53 \) by overexpressing exportin-1, thus preventing its binding to DNA and its
anti-proliferative activities (215). The addition of KPT-185 and KPT-355, engineered molecules that inhibit exportin-1 on canine mammary carcinoma cells, in vitro induced cell cycle arrest, apoptosis, and reduced growth (216).

**Anti-cyclooxygenases**

Cyclooxygenases (COX) are a group of enzymes that catalyzes the conversion of arachidonic acid to prostanoids (prostaglandins, prostacyclins, and thromboxanes). In humans and animals, COX exist in three isoforms: COX-1, constitutively found in most cells, in charge of maintaining homeostasis, protection of the gastric mucosa, and regulation of platelet aggregation and renal blood flow; cyclooxygenase-2 (COX-2), an inducible isoform that is detected in neoplastic and normal cells induced through several stimuli (e.g., mitogens, growth factors, hormones, and pro-inflammatory cytokines); and COX-3, which is expressed mainly in the central nervous system and the aortic wall (217, 218).

Since 1897, with the development of aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) have been developed as analgesic, antipyretic, anti-inflammatory, and anti-rheumatic treatment (219). However, a meta-analysis showed a remarkable preventive effect against colon cancer (220). Other studies found the same effects in different types of cancer, such as breast cancer (221). Nevertheless, the adverse effects of long-term use of NSAIDs were significant, mainly gastrointestinal bleeding, increased uric acid, and coagulation inhibition, among others (222). In an attempt to avoid these adverse effects and target specifically COX-2 for its participation in the neoplastic process, selective COX-2 inhibitors were designed and named as “coxibs.” Experimentally, both NSAIDs and coxibs have been shown to inhibit tumorigenesis by inhibiting cancer cell growth and proliferation, modulating apoptotic activity, reducing the metastatic and invasive potential of cells, and by inhibiting angiogenesis (223, 224).

Coxibs had been related in human medicine to thrombotic cardiovascular events, myocardial infarction, and stroke, especially in long-term use (225). Although subsequent meta-analysis revealed that the risk of cardiovascular events was not related to the usage of coxibs (226), the use of coxibs as adjuvants in the treatment of human cancer is an ongoing intense field of research, especially in combination with chemotherapeutic agents (227).

COX-2 is overexpressed in various canine epithelial malignant tumors, including ovarian carcinomas, prostate carcinomas, urothelial and transitional cell carcinomas, colorectal and small intestine tumors, squamous cell carcinomas, osteosarcoma, and melanoma (228).

Since 2003, COX-2 expression has been reported in both benign and malignant canine mammary tumors (229) (Figure 11). Cyclooxygenase-2 is overexpressed in 83–95% of the CMC in association with characteristics of aggressiveness, such as high histological and nuclear grades, mitotic index, and lymph node metastasis (230–232). COX-2 has an important role in the angiogenesis of CMC: its presence is correlated with MVD and EGFR and VEGF expressions (233). Interestingly, in canine IMC, which is characterized by exacerbated angiogenesis, lymphangiogenesis, and lymphangiotropism, COX-2 is associated with higher lymphatic proliferation index, VEGF-D (a lymphangiogenic factor), and its receptor VEGFR-3; in contrast, COX-2 is associated with VEGF-A in non-inflammatory mammary cancer (234), indicating a different role of COX-2 in the angiogenesis of IMC.

Moreover, COX-2 also participates in the immunomodulation of the tumor microenvironment by promoting the M2 phenotype of macrophages, inhibiting antigen-presenting cells and reducing CD8+ T cells, all of which impair the antitumoral immune response (235).

The non-selective (anti-COX 1 and 2) NSAIDs meloxicam and piroxicam have been tested in vitro against CMC cells, which resulted in apoptosis induction, migration inhibition, and cell cycle arrest (236, 237). Additionally, piroxicam was utilized in a xenograft model of CMC, showing a tumor size reduction (238). Further, a small group of dogs with IMC were treated with piroxicam. The mean survival time was significantly longer in dogs treated with piroxicam compared to those treated with doxorubicin-based chemotherapy (239).

Due to the availability of COX-2 selective drugs in veterinary medicine (firocoxib, deracoxib, cinicoxib, robenacoxib, and mavacoxib), their effectiveness in CMC has been studied in cell lines, mice xenografts, and, in lesser extent, in clinical trials. Celecoxib and mavacoxib have been used in CMC cell lines, showing their cytotoxic activity, proliferation inhibition, apoptosis induction, and migration reduction, even in those cell lines with low COX-2 expression, suggesting their extraordinary therapeutic applicability in COX-2-positive or COX-2-negative CMC (217, 240, 241). Deracoxib has been proven alone or in combination with piroxicam, displaying a significant decrease in cell viability, achieving an arrest in cell cycle, and induction of apoptosis in CMC cell lines (237). Additionally, when combined with doxorubicin, a strong synergistic activity was seen, allowing to reduce the dose of doxorubicin in vitro (242). In CMT xenografted mice, deracoxib was given in comparison to piroxicam, although its effect was lower than piroxicam. Nevertheless, the authors did not evaluate the dose of deracoxib, thus concluding that mice could have been underdosed (238).

In a clinical trial, piroxicam showed an increased in OS compared to doxorubicin in 12 IMC-bearing dogs with COX-2-positive tumor cells (239). Likewise, in a case–control prospective study, firocoxib showed higher disease-free survival and overall survival compared to mitoxantrone in dogs with highly malignant CMT-expressing COX-2 (18).

As mentioned above, in the available clinical trials on the use of NSAIDs/coxibs in CMC, patients had COX-2-positive tumors. However, in vitro evidence has shown that anti-COX-2 therapy may be therapeutically useful regardless of the COX-2 expression status (217).

As a conclusion, the anti-COX-2 drugs approved for their use in veterinary medicine are being used in veterinary clinics as anti-inflammatory drugs, but also as an adjuvant in neoplastic patients, no matter the expression of the enzyme in the patients’ tumors and, in many cases, the lack of proper clinical trials.
Epithelial–Mesenchymal Transition Inhibition: Cancer Stem Cells

Epithelial–mesenchymal transition (EMT) is a complex process in which epithelial cells lose their characteristics and acquire mesenchymal properties. It is essential in different embryonic stages and organ development, wound healing, and neoplastic infiltration and metastasis, cell motility, and invasiveness (243). By this process, epithelial cells undergo detachment and acquire the capacities of motility and invasiveness through the extracellular matrix to finally enter blood and lymphatic vessels and colonize different organs.

EMT is driven by the dysregulation of the adhesion molecules (mainly cadherins). Cadherins are calcium-dependent adhesion molecules responsible for cell-to-cell attachment and for maintenance of the normal structure and polarization of tissues. The most relevant are P-cadherin (placental cadherin), N-cadherin (neural cadherin), and E-cadherin (epithelial cadherin) (244). In normal human mammary tissue, E-cadherin is expressed in luminal epithelial cells, while P-cadherin is found in myoepithelial cells (245). In HBC, E-cadherin is known to be an inhibitor of metastasis, and its downregulation or inactivation leads to aggressive forms of breast cancer, EMT, lymphovascular invasion and metastasis (246, 247), as well as higher histological grade (248). Likewise, in CMC, reduction of E-cadherin expression has been related to large size and ulceration of mammary tumors (249), infiltrative growth, high histological grade, and lymph node metastasis (250–253), as well as shorter overall and disease-free survivals (254). EMT involves a range of transcription factors, including zinc finger E-box-binding homeobox 1 and 2 (ZEB1 and ZEB2), Snail, signal transducer and activator of transcription 3 (STAT3), and Twist, as well as transcriptional targets such as transforming growth factor-β (TGF-β), all of which suppress the expression of epithelial-associated molecules (E-cadherin and membranous β-catenin) and promote molecules associated with mesenchymal cell phenotypes (N-cadherin, cytoplasmic β-catenin, fibronectin, and vimentin) (255, 256). In CMC, Snail and ZEB2 have been proven to be related to E-cadherin downregulation in invasive micropapillary carcinomas (257, 258).

Not only EMT is required for successful metastatic colonization, but also cells that are capable of initiating tumorigenesis may undergo self-renewal and differentiate into various subsets of cells found in the primary tumor; these cells are called cancer stem cells (CSCs) (259). Molecular pathways
that lead to EMT are markedly overlapping with those of CSC generation, allowing neoplastic epithelial cells to pass through the EMT and generate a population of CSCs (260). Additionally, CSCs are associated with therapeutic resistance (261).

Several reviews are centered on EMT as a source of metastasis, CSC generation, and therapy resistance in HBC (261–263). Likewise, studies on CMC have revealed a positive correlation between cells undergoing EMT and higher tumor grade and metastasis (264) and have identified ZEB1 and ZEB2 as potential therapeutic targets in CMT cells in vitro, intended to restore E-cadherin and inhibit EMT, although to date, there are no drugs targeting these molecules (265).

A number of attempts have been made for the therapeutic targeting of EMT and CSCs in HBC and CMC, which are presented below.

As aforementioned, melatonin is capable of disrupting estrogen-dependent cell signaling. In addition, in vitro studies on HBC and CMC cell lines have shown that melatonin is also able to reduce EMT through the degradation of β-catenin, an E-cadherin repressor (266), reducing cell migration, invasion, and CSC generation (267, 268). Significantly, the effect of melatonin is higher on ER+ CMC cells overexpressing melatonin receptors (269). In a more recent in vitro study, CMC cell lines treated with melatonin plus IL-25 significantly reduced cell viability, increased caspase-3-mediated apoptosis, and reduced pro-angiogenic VEGF-A (268).

Metformin, a commonly used drug in human medicine as oral treatment for type II diabetes, is being experimentally studied due to its anti-carcinogenic properties associated with the inhibition of the EMT process. Metformin has been shown to inhibit EMT in HBC cells by repressing the drivers of TGF-β (270). In vitro studies on CMC cell lines proved that metformin is able to induce cell cycle arrest and reduce cell migration and N-cadherin expression while increasing E-cadherin expression. The foreseen effect was ever more prominent when combined with silencing of TGF-β in the CMC cell line (271). In CMC xenografted mice treated with metformin, there was a significant decline in CSCs and reduction of lung metastasis and tumor growth (272–274). When combined with LY294002 (an inhibitor of the PI3K/AKT/mTOR pathway with anti-angiogenic properties), metformin showed a marked reduction in viability and tumor cell growth in vitro, while in CMC xenografted mice, both drugs decreased the tumor size and showed an important anti-angiogenic effect (reduction of VEGF-A expression and MVD) (275).

Cancer stem cells are also characterized by the presence of multidrug-resistant (MDR) adenosine triphosphate-binding cassette (ABC) transporter efflux pumps, influencing chemotherapy resistance in cancer due to their capacity to export a wide variety of cell substances (276). It has been seen that the Wnt/β-catenin pathway can upregulate the multidrug resistance protein 1 (MDR-1). Simvastatin (a lipid-lowering drug) has been studied in mammary oncology due to retrospective evidence of an improved OS and recurrence-free survival in HBC-bearing patients (277), and further in vitro analyses revealed an induction of apoptosis on HBC cell lines (278). In vitro studies using simvastatin on CMC cell lines showed that the expressions of MDR-1 and β-catenin were reduced, contributing to a chemosensitizing effect on CMC cells (279). Furthermore, when combined with doxorubicin, simvastatin exhibited a synergic cytotoxic effect on CMC cells (280). However, despite good in vitro results, discouraging large meta-analyses have found no significant benefit from the use of simvastatin in patients suffering from HBC (281–283).

Artemisinin, a derivate from the plant Artemisia annua, employed in Chinese traditional medicine, was discovered by Tu Youyou in 1972 for the treatment of malaria. By this discovery, Tu Youyou was co-recipient of the 2015 Nobel Prize in Medicine. Studies on HBC cells showed the in vitro suppression of N-cadherin, involved in EMT (284). Additionally, synthetic derivates of artemisinin (e.g., artesunate) are capable of inducing caspase-dependent apoptosis in HBC cells (285). The in vitro treatment of CMC cells with an artemisinin derivative (dihydroartemisinin, DHA) showed an inhibition of cell migration and invasiveness by downregulating the expression of EMT-related genes (Slug, ZEB1, ZEB2, and Twist) (286). In human medicine, a few phase I clinical trials have been conducted without significant adverse effects (287, 288), although a patient with HBC on artemisinin treatment showed toxic encephalopathy (289). Knowing the neurotoxicity of artemisinin in experimental animal models (290), a phase I clinical trial should be performed in domestic animals before giving any general recommendation on its use in veterinary patients.

**IMMUNOTHERAPY AS A PROGRESSING TARGET**

In human oncology, after decades of depleting the immune system of cancer patients with chemotherapy, the tendency is now to protect and increase the action of the immune system against cancer cells (291). Cancer immunoediting is the process by which the immune system tries to destroy neoplastic cells and is composed of three steps: elimination, equilibrium, and escape (292). In the first step, the host’s immune system responds to the newly formed tumor and removes it prior to any clinical evidence. If some resistant clones of the tumor are present, they survive and remain inactive in the second stage, the equilibrium. In the escape or evasion stage, tumor cells improve their ability to evade the immune system, eventually leading to clinical manifestation (293). Some of the evasion mechanisms are as follows: decreased or absent expression of major histocompatibility complex (MHC) molecules, activation of immunoregulatory pathways (immune checkpoints) such as the inhibitory molecule CTLA-4 (cytotoxic T lymphocyte antigen 4), upregulation of PD-L1 (programmed death ligand 1) that binds to the PD-1 receptor on T lymphocytes and represses their function, secretion of immunosuppressive factors such as TGF-β, interleukin-10, and VEGF, as well as induction of regulatory T cells (294). Although many of these mechanisms are already known, the true interplay between the pathways, and the interaction between tumor cells and the immune system and microenvironment, is still largely unknown.
Some mAbs that target specific molecules that intervene in a signaling pathway (e.g., anti-HER-2) have been mentioned in this review. In this section, we will discuss an intriguing class of antibodies designed to modulate the immune response and the use of vaccines, including cellular immunotherapy and DNA vaccines. Cellular immunotherapy, in particular hybrid cell vaccines, are based on cells generated by fusing antigen-presenting cells (i.e., dendritic cells) with the tumor cells of the recipient, intending to present to the immune system the whole tumor-associated antigens and activate an immune response (295). DNA vaccines are based on the introduction of one or more genes (e.g., tumor antigen, cytokines, etc.) into plasmids that are delivered into the patient with the subsequent expression of the introduced gene (296). Finally, the role of oncolytic viruses, which show selective cytotoxicity toward cancer cells and may favor the restoration of the anticancer immune function, will be reviewed (297).

The most successful human immunotherapies to date include mAbs against lymphoma antigens (i.e., CD20—rituximab) as well as mAbs against immune checkpoint molecules such as PD-1 (i.e., pembrolizumab, atezolizumab, and nivolumab) and CTLA-4 (i.e., tremelimumab and ipilimumab), which are able to release the cytotoxic activity of T lymphocytes and activate other immune responses such as antigen presentation and cytokine production (298). Besides targeting immune checkpoint molecules, other immunotherapies are being developed, such as tumor-specific cytotoxic immune cells and cytokines. However, although some cancers, such as melanoma and lymphoma, respond well to immunotherapy, other solid tumors still have weak responses (299).

Cancer cell lines and mouse models, including transgenic mice and patient-derived xenografts, have been extremely useful in the study of human cancer, yielding valuable insights into cancer biology, genetics, and biochemistry (300). However, they have limitations and lack essential features inherent only to spontaneous cancers, like an intact complex immune system (301, 302). Because normal immunocompetent mice reject human tumor grafts, there are no preclinical experimental models to investigate immunotherapy for cancer patient tumors. Canine patients with CMC have been used as an intermediate model in several clinical trials with novel immunotherapy (303).

Several clinical trials have revealed relevant information regarding canine cancer immunotherapy in osteosarcoma, lymphoma, melanoma, meningioma, bladder cancer, soft tissue sarcoma, and hemangiosarcoma using multiple immunotherapeutic approaches (DNA vaccines, cellular immunotherapy, mAbs, bacteria, etc.) (303–310), which are out of the scope of this review.

Antibody Immunotherapy

Even though HBC is not considered a highly immunogenic cancer, immunotherapeutic strategies are being successfully tested especially against TNBC (311). Proof of this is that the FDA approved an immunotherapy for advanced PD-L1+ TNBC, atezolizumab (anti-PD-1 mAB), in combination with paclitaxel (312). Another anti-PD-L1 mAb, pembrolizumab, has also been shown to improve the progression-free survival in PD-1+ TNBC when combined with paclitaxel, gemcitabine, carboplatin, or eribulin (313, 314). Although PD-1 has been detected in CMTs (315, 316), no attempt has been made to use anti-PD-1 or anti-PD-L1 mAbs against CMC, perhaps due to cost restrictions. The only published clinical trial with mAbs against CMC (including IMC) used the mouse monoclonal antibody BR96, which recognizes a specific antigen (Lewis’-related carbohydrate, Le^x) expressed in several solid tumors and gastrointestinal epithelium, conjugated with a truncated, non-binding derivate of Pseudomonas exotoxin A. Stable disease or partial response was achieved in IMC cases, as well as neutralizing antibodies (317). In addition to this, in 2014, a canine anti-EGFR-1 mAb was developed, but it never reached the clinical or preclinical level (151).

**Cellular Immunotherapy**

Cellular immunotherapy is an emerging field of research in which immune cells are extracted, modified, and reinfused into the patient (318). In HBC, two main types of cellular immunotherapy have been studied: adoptive cell therapy (ACT, based on T lymphocytes) and dendritic cell therapy (319). ACT is based on the isolation of T lymphocytes in the resected tumor, in vitro expansion or modification, and subsequent reinfusion (318). Few information on HBC are available to date. Direct T lymphocyte reinfusion in combination with pembrolizumab led to a complete durable regression in a patient with chemotherapy-refractory HBC (320). Chimeric antigen receptor (CAR) T cell therapy is a type of modification where the receptor is engineered to target a specific antigen and combine antigen-binding and T cell-activating functions, hence recognizing antigens in the absence of the presentation by the MHC (321). To date, only preclinical studies have been published using HER-2, mucin 1 cell surface associated (MUC-1), mesothelin (MSLN), epithelial cell adhesion molecule (EPCAM), and carcinoembryonic antigen (CEA) as targets (322). On the other hand, in dendritic cell therapy, the cells are isolated and combined with tumor antigens before reinfusion into the patient (319). Despite clinical settings being currently limited to phase I/II human trials, preclinical studies on HER-2-loaded and cyclin D1-loaded dendritic cell vaccines have been shown to significantly inhibit the HBC xenografted tumor growth in mice (323). Recently, autologous hybrid-cell vaccines were produced for a clinical trial in CMC as an intermediate model for HBC. The therapy was combined with immunostimulatory oligonucleotides and ganciclovir and achieved 3.3 times longer median survival times than the control group, except for the case of IMC, which only resulted in a median of 42 days (324).

**DNA Vaccines**

DNA, or gene-based, vaccines are intended to deliver functional genes to the target cells for the expression of functional proteins (325). Since naked DNA is readily accessible for endonucleases, the DNA needs an effective and safe delivery method, which can be biological (e.g., viruses and bacteria) or non-biological (e.g., physical methods such as electroporation or chemical methods such as nanoparticles) (326). In HBC, different delivery methods have been tested to transport tumoral antigens, such
as HER-2, p53, MUC1, Twist, and mammaglobin-1, as well as immunostimulatory molecules such as IL-6 and IL-12 (326, 327).

Since the intravenous administration of IL-12 has been associated with grave toxicity in humans (328), a clinical trial using nine dogs, one of them with a mammary tumor, used intratumoral IL-12 (plasmid DNA by electroporation) as an immunostimulatory cytokine. Despite transient increases in serum and tumor IL-12 and IFN-γ, no clinically relevant outcome benefits were seen (329). Similarly to this, recombinant viral vaccines, based on replication-defective recombinant adenoviruses, have been proven to be safe and to induce strong antibody and cellular antigen-specific immune responses in non-human primates (330). A study evaluated the ability of DNA electroporation and a recombinant adenovirus serotype 6, both expressing telomerase reverse transcriptase (overexpressed in tumor cells, while low to absent in normal cells) and HER-2, to induce immune responses in healthy dogs against these proteins. A detectable and long-standing cellular and humoral immune response was detected in the absence of side effects or autoimmunity (331).

An anticancer DNA vaccine based on p62 (a protein involved in selective macroautophagy that is dispensable for most tissues, but essential for the development and survival of tumors) was utilized in CMC xenografted mice and dogs bearing mammary carcinomas. The intramuscular administration of the p62 DNA vaccine achieved a partial response or stable disease in the absence of noteworthy secondary effects. Antitumoral activity was related to lymphocyte infiltration, particularly T lymphocytes, and tumor encapsulation via fibrosis (332, 333).

Another clinical trial with dogs presenting CMC utilized nanoparticles carrying DNA plasmids coding canine interferon-β and herpes simplex virus (HSV) thymidine kinase (a suicide gene), which were injected into the tumor bed during mastectomy; afterwards, subcutaneous injections of the nanoparticles associated with a human granulocyte–macrophage colony-stimulating factor and interleukin-2, mixed with allogeneic mammary carcinoma extracts, were periodically administered. The therapy was well-tolerated; only one out of 26 patients had recurrence and none displayed distant metastasis, and overall survival was also improved (334).

### Oncolytic Viruses

Oncolytic viruses show selective cytotoxicity toward cancer cells and may favor the restoration of immune anticancer function (297). Clinical trials with oncolytic viruses are currently ongoing in humans, and two viruses have been approved for commercial use. The first, H101 or Oncorine®, is an adenoviral construct with an E1B deletion (in order to avoid replication in normal cells), approved in China in 2005 for the treatment of head-and-neck squamous cell carcinoma (335). The second, T-VEC or Imlygic™, is an engineered herpes simplex virus type I (HSV-1) that expresses the human granulocyte–monocyte colony-stimulating factor as an immune stimulant, approved in 2015 by the United States FDA for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma after initial surgery (336). In veterinary medicine, a number of viruses with natural oncolytic capacity, as well as engineered viruses, are being studied for several neoplasms (337, 337–349). Among them are morbillivirus, poxvirus, and reovirus.

### Oncolytic Morbillivirus

In human medicine, the measles virus has demonstrated an oncolytic potential since anecdotal reports describing the regression of hematopoietic neoplasms after natural infection with measles virus (350). In HBC, the measles virus has shown a strong cytolytic effect in cancer cell lines in vitro (351–354). Additionally, attenuated measles virus has been proven to overcome chemoresistance in HBC cells. Several studies in mice, however, showed that viral replication also existed in the organs and cells of infected mice and not only in the targeted tumor cells (355–357). Therefore, some modifications have been done to the viral strains. For instance, a recombinant measles virus strain was created by eliminating its ability to bind to the signaling lymphocyte activation molecule (SLAM), a major receptor used by the wild-type virus to infect immune cells in naturally occurring infections. Cancer cells do not express SLAM molecules, but the measles virus is able to use the Nectin-4 receptor to bind and infect the cell (351). Interestingly, Nectin-4 expression has been found in HBC cells (358) and in 45% of CMT tissue samples and in CMC cell lines. Recombinant measles virus strain exerts cytotoxic effects in Nectin-4-expressing CMC cell lines. In Nectin-4-expressing CMC xenografted mice, this oncolytic therapy showed significant suppression of tumor growth without any noticeable adverse effect (340).

Canine distemper virus (CDV) has been shown to induce apoptosis in the cerebellum and lymphoid tissue of naturally infected dogs through the extrinsic pathway, activating caspase-8 and caspase-3 (359, 360). Therefore, this morbillivirus is considered to be a candidate for potential treatment in canine malignancies. An attenuated strain of CDV showed a substantial oncolytic effect in CMC cells both in vitro and in xenografted mice, without significant adverse events, by inducing apoptosis through the same pathways as natural infection (extrinsic pathway) with participation of nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) (346, 361).

### Oncolytic Poxvirus

Several studies on the use of multiple strains of vaccinia virus (362–366) have demonstrated the in vitro and preclinical effects against HBC, which have led to a randomized phase III clinical trial in patients with metastatic HBC in which the use of a poxviral vaccine in combination with docetaxel resulted in an increase in progression-free survival (367).

Two oncolytic strains of vaccinia virus (strain GLV-1h68 and strain GLV-5b451 expressing GLAF-2, an antibody against VEGF) have been tested against CMC cells in vitro or in xenografted mice, resulting in efficient infection and lysis of cells in vitro while achieving significant tumor growth inhibition in vivo with strong inflammatory and oncolytic-associated effects (368, 369) and a reduction of MVD in the tumors treated with strain GLV-5b451 (337).

An attenuated form of *Myxoma virus* lacking the *serp2* gene (an anti-apoptotic virulence factor) was used to evaluate its
oncolytic activity in canine mammary cancer cells and showed severe cytopathic effects and adequate viral replication (370).

Oncolytic Reovirus
The oncolytic virus pelareorep (REOLYSIN®) is a non-modified serotype 3 reovirus strain that has shown antitumor activity in clinical and preclinical models, especially in pancreatic cancer, and currently is being tested in clinical trials to assess its efficacy as an oncolytic agent against several cancers. In HBC cells, REOLYSIN® infection in the presence of DNA-damaging agents enhances infection and triple-negative breast cancer cell killing by the reovirus (371). REOLYSIN® was tested in CMC cells in vitro and in xenografted mice, demonstrating significant cell death via caspase-3-mediated apoptosis (338). When combining this oncolytic therapy with low doses of paclitaxel, carboplatin, gemcitabine, or toceranib, its activity was enhanced with all the therapeutic agents, except toceranib (341). A series of cases of dogs with various malignancies, which included two cases of CMC (one IMC and one non-IMC), were treated with intratumoral or intravenous REOLYSIN®. Less than 50% of the dogs presented grade I or II adverse effects, which included vomiting, diarrhea, and inflammation of the injected tumor. Dogs did not shed virus and had elevated neutralizing antibodies. No specific information about the antitumoral response in CMC patients was provided (341, 345).

OTHER ADJUVANT THERAPIES

Nanotechnology
Nanotechnology has been evolving rapidly in recent years, providing new therapeutic tools for several diseases. Nanoparticles are defined as particles below 100 nm of dimension, although their surface is generally large enough to bind and carry therapeutic compounds (372). Nanoparticles have been proposed as drug carriers in cancer treatment since they can increase drug accumulation in target tissues, optimizing the therapeutic effect (373).

Several nanoparticle-based delivery platforms have been approved by the US FDA, and two nano-based drugs are already in the market for HBC—Doxil® (doxorubicin-loaded nanoparticles) and Abraxane® (albumin-bound paclitaxel-loaded nanoparticles)—whose coating evades the immune system, allowing a precise targeting delivery (374). Additionally, several clinical trials with HBC patients are currently under study using these delivery platforms to carry doxorubicin, paclitaxel, cisplatin, irinotecan, annamycin (synthetic derivate of doxorubicin), and docetaxel (375–379).

In dogs, doxorubicin is a commonly used chemotherapeutic for CMC. However, its toxicity is dose-limiting, reducing treatment efficacy (58). Aldoxorubicin (a prodrug of doxorubicin bound to albumin, which is cleaved from the drug in the acidic tumor microenvironment) (380) was constructed into nanofiber to deliver into CMC cell lines, manifesting a clear and persistent cytotoxic effect (400, 401).
The edible wild ginger *Zingiber zerumbet* contains several phytochemicals with healing properties; zerumbone is one of the most important due to its antitumor, anti-inflammatory, antioxidant, antimicrobial, antineoplastic, hepatoprotective, and immunomodulatory activities (402). However, its poor absorption and bioavailability are the main issues for its therapeutic application (403). Therefore, nanostructured lipid carriers loaded with zerumbone have been used as an apoptogenic agent in several neoplastic human and canine cell lines, including CMC. The effect was attributable to increases in caspase-8, caspase-9, caspase-3, and caspase-7 (404).

The last one of the herbal compounds that have been used for canine mammary tumors is berberine, an isoquinolone alkaloid of the plant *Berberis vulgaris* L. that inhibited the proliferation of CMC cells in vitro (405).

**Old Drugs as New Therapies**

Ivermectin is a well-known anti-parasitic agent used to treat a variety of canine parasitic infestations. The mechanism of action of ivermectin in parasites is due to blockade of the parasite chloride channel (406). Currently, ivermectin has been linked to a potential anticancer effect in different tumor types, including breast cancer (407). In vitro studies using ivermectin in CMC cell lines, and further in xenografted mice, effectively inhibited cell growth in a dose- and time-dependent manner. The effects were associated with cell cycle arrest via the downregulation of CDK4 and cyclin D1 expressions and reduced WNT/β-catenin signaling (408).

Selenium possesses different anti-neoplastic mechanisms: promotion of cell apoptosis, anti-angiogenesis, and immune system regulation. Also, its antioxidant effect may reduce the toxicity of conventional chemotherapeutics if used in combination (409). Different selenium compounds (sodium selenite, methylseleninic acid, and methylselenocysteine) showed in vitro anti-proliferative effects on CMC that were even greater when combined with cyclophosphamide. An increase of apoptosis, downregulation of pro-angiogenic VEGFA, angiopoietin-2, and hypoxia-inducible factor-1 alpha, and upregulation of the anti-angiogenic and anti-proliferative phosphatase and tensin homolog (PTEN) were the major features (409). In further CMC xenografted mouse models, the different selenium compounds significantly inhibited tumor growth, generated large necrotic areas, and reduced the MVD compared to the untreated control. This in vivo study also found a reduction in pro-angiogenic factors (VEGFA, PDGF, and angiopoietin-2) (410).

Salinomycin is an ionophore antibiotic isolated from *Streptomyces albus*, which is widely used in farm animals as an anticoccidial drug (411). Several studies with HBC cell lines demonstrated that salinomycin inhibits in vitro growth by inducing apoptosis and selectively targeting CSC (412–419). Likewise, salinomycin was found to have a profound effect in CMC cell lines by selectively depleting canine mammary CSC and inhibiting the Wnt/β-catenin signaling pathway (preventing cell invasion and migration) (420, 421).

**DISCUSSION**

A total of 71 studies focused on adjuvant therapies in CMTs, not including those related to surgery or conventional chemotherapy, were analyzed in this review. The majority of those studies were performed in vitro (49 studies); 15 used xenografted mice to study CMC (in total, 15 papers of mouse models of CMTs). Only six of those investigations done with CMC cells in vitro or in mouse models, have reached the clinical setting (138, 143, 239, 332, 333, 341, 345, 399).

Setting clinical studies of conventional chemotherapy aside, to date, 18 clinical trials have been conducted in dogs with CMC, and a third of them are new immunotherapies, which demonstrate the usefulness of spontaneous CMC as a natural model for the study of HBC in a natural model with a complete immune system. They are also a reflection of the current state of cancer research and the important trend to stimulate the immune system against cancer cells (291). In spite of the relevance of such investigations in dogs, the number of patients recruited in them is very low to obtain conclusive and extrapolative results: five of the 18 clinical studies were done with less than eight dogs with mammary cancer; four of them with less than three dogs. In addition, two more studies were executed in non-tumor-bearing dogs. As a main conclusion, larger prospective randomized studies are needed to provide a strong level of evidence that allows a widespread use of some of these new approaches. Considering that CMTs are the most common malignancy in dogs and the low rate of success of routine adjuvant therapies (i.e., conventional chemotherapy), these clinical trials seem not to be enough. Significantly greater effort must be made to generate knowledge and develop canine-specific targeted therapies. There is a great need for well-planned large prospective randomized clinical trials in dogs with CMC to obtain valid results for both species, humans and dogs, on the use of new therapies.

Following the One Health concept, human and veterinary oncology will have to join forces to take advantage of both the economic and technological resources that are invested in HBC research, together with the innumerable advantages of dogs with CMC as a spontaneous animal model.

**AUTHOR CONTRIBUTIONS**

LP and GV devised, structured, and wrote the manuscript. GV reviewed the literature. AA-D and GV performed the immunohistochemical slides and the photographs. All the authors reviewed and corrected the manuscript.

**FUNDING**

GV has a PhD grant funded through the Mexican Council for Science and Technology (CONACYT), 515916. AA-D has specialization in Veterinary Pathology (ECVP Residency) grant funded by the Complutense University of Madrid, 69/2018. The research of the Oncology Mammary Unit of the Complutense Veterinary Teaching Hospital was funded by the Spanish Ministry of Science, Innovation and Technology, project PGC2018-094516-B-I00.
REFERENCES

1. Moe L. Population-based incidence of mammary tumours in some dog breeds. J Reprod Fertil Suppl. (2001) 57:439–43.

2. Salas Y, Marquez A, Diaz D, Romero L. Epidemiological study of mammary tumours in female dogs diagnosed during the period 2002-2012: a growing animal health problem. PLoS ONE. (2015) 10:e0127381. doi: 10.1371/journal.pone.0127381

3. Goldschmidt MH, Peña L, Zappulli V. Tumors of the mammary gland. In: Meuten DJ, editor. Tumors in Domestic Animals. Fifth ed. Danvers, MA: John Wiley & Sons, Inc. (2017). p. 723–65. doi: 10.1002/9781119181200.ch17

4. Sorenmo K, Schoenrock D, Baumgärtner W, Nolte I. Postoperative adjuvant treatment of invasive malignant mammary gland tumors and its comparison to human breast cancer. J Reprod Fertil Suppl. (2018) 82:737–46. doi: 10.1530/JR F-18-0094.1

5. Perou CM, Sorell T, Esen MB, van de Rijn M, Jeffery SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. (2000) 406:747–52. doi: 10.1038/sj.onc.1213100

6. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. (1991) 19:403–10. doi: 10.1111/1365-2559.1991.tb00229.x

7. Bocker W, Moll R, Poremba C, Holland R, Van Diest PJ, Dervan P, et al. Myoepithelial cell lineages: a new cell biological concept. Lab Invest. (2014) 94:1166–80. doi: 10.1038/labinvest.2014.013

8. Marconato L, Lorenzo RM, Abramo F, Ratto A, Zini E. Adjuvant gemcitabine after surgical removal of aggressive malignant mammary gland tumours in dogs with doxorubicin and docetaxel. J Vet Intern Med. (2006) 20:1184–90. doi: 10.1111/j.1939-1676.2006.tb00720.x

9. Arenas C, Peña L, Granados-Soler JL, Pérez-Alenza MD. Adjuvant therapy for highly malignant canine mammary tumours: cox-2 inhibitor versus chemotherapy: a case–control prospective study. Vet Rec. (2016) 179:125. doi: 10.1136/vetrecr.2016.013998

10. Tran CM, Moore AS, Frimberger AE. Surgical treatment of mammary carcinomas in dogs with or without postoperative chemotherapy. Vet Comp Oncol. (2016) 14:252–62. doi: 10.1111/vco.12092

11. Nguyen F, pena L, Ibsich C, Loussouarn D, Gama A, Rieder N, et al. Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors. Breast Cancer Res Treat. (2018) 167:635–48. doi: 10.1007/s10549-017-4548-2

12. Ruttenman G, Withrow S, EGM. Tumors of the mammary gland. In: Withrow SJ, MacEwen E, editors. Small Animal Clinical Oncology. 3rd ed. Philadelphia, PA: WB Saunders (2001). p. 455–77.

13. Valdivia et al. Therapies in Canine Mammary Cancer.
38. Gama A, Alves A, Schmitt F. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification.Virchows Archiv. (2008) 453:123–32. doi: 10.1007/s00428-008-0644-3

39. Sassi F, Benazzi C, Castellani G, Sarli G. Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry. BMC Vet Res. (2010) 6:5. doi:10.1186/1746-6148-6-5

40. Ressel L, Puleio R, Loria GR, Vannozzi I, Millanta F, Caracappa S, et al. HER-3 expression in canine morphologically normal, hyperplastic and neoplastic mammary tissues and its correlation with the clinical outcome. Res Vet Sci. (2013) 94:299–305. doi: 10.1016/j.rvsc.2012.09.016

41. Shinoda H, Legare ME, Mason GL, Berkbigler JL, Afzali MF, Flint AF, et al. Significance of Erk, HER2, and CAV1 expression and molecular subtype classification to canine mammary gland tumor. J Vet Diugn Invest. (2014) 26:390–403. doi:10.1177/1040638714527289

42. Im KS, Kim NH, Lim HY, Kim HW, Shin JI, Sur JH. Analysis of a new histological and molecular-based classification of canine mammary neoplasia. Vet Pathol. (2014) 51:549–59. doi:10.1093/vp/300988513498780

43. Varallo GR, Gelaleti GB, Maschio-Signorini LB, Moschetta MG, Lopes JR, De Nardi AB, et al. Prognostic phenotyping classification for canine mammary tumors. Oncol Lett. (2019) 18:655–53. doi:10.3892/ol.2019.11052

44. Seung BJ, Cho SH, Kim SH, Lim HY, Sur JH. Quantitative analysis of HER2 mRNA expression by RNA in situ hybridization in canine mammary gland tumors: comparison with immunohistochemistry analysis. PLoS ONE. (2020) 15:e0229931. doi:10.1371/journal.pone.0229931

45. Burrai GP, Tanca A, De Miglio MR, Abbondio M, Pisanu S, Polimans M, et al. Investigation of HER2 expression in canine mammary tumours by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer? Tumor Biol. (2015) 36:9083–91. doi:10.1007/s13277-015-3661-2

46. Tsuboi M, Sakai K, Maeda S, Chambers JK, Yonezawa T, MatsuKI N, et al. Assessment of HER2 expression in canine urothelial carcinoma of the urinary bladder. Vet Pathol. (2019) 56:369–76. doi:10.1177/0300985818817024

47. Fabelo C, Selmic LE, Huang PC, Samuelson JP, Reagan JK, Kalamaras A, et al. Evaluating optical coherence tomography for surgical margin assessment of canine mammary tumors. Vet Comp Oncol. (2020). doi:10.1111/vco.12632. [Epub ahead of print].

48. Favril S, Brioscì C, Vanderperren K, Abma E, Stock E, Devriendt et al. Adjuvant anthracycline-based vs metronomic chemotherapy vs no chemotherapy: randomised evaluation of toxicities from combined metronomic and maximal-tolerated chemotherapy in canine splenic haemangiosarcoma. J Vet Intern Med. (2014) 28:259–66. doi:10.1111/j.1939-1676.2014.07018.x

49. Sorenmo K. Canine mammary gland tumors. Vet Clin North Am Small Anim Pract. (2003) 33:573–96. doi:10.1016/S0301-5616(03)00020-2

50. Lavalle GE, De Campos CA, Bertagnolli AC, Cassali GD. Canine mammary gland neoplasms with advanced clinical staging treated with carboplatin and cyclooxynegase inhibitors. In Vivo. (2012) 26:375–9.

51. Poirier VJ, Hershey AE, Burgess KE, Phillips B, Turek MM, Forrest LJ, et al. Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. J Vet Intern Med. (2004) 18:219–22. doi:10.1111/j.1939-1676.2004.tb06164.x

52. von Euler H, Rivera P, Nyman H, Häggström J, Börja Ö. A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs. Vet Comp Oncol. (2013) 11:243–55. doi:10.1111/j.1476-5289.2011.00314.x

53. Marconato L, Chalfon C, Finotello R, Sabattini S, Felisberto R, Pizzoni Failing K, Richter A, Wehrend A. Mammary tumor recurrence in bitches after regional mastectomy. Vet Surg. (2008) 37:82–6. doi:10.1111/j.1532-950X.2007.00315.x

54. Schoos A, Knab VM, Gabriel C, Tripolt S, Wagner DA, Bauder B, et al. In vitro study to test the efficacy of CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary tumours. Vet Comp Oncol. (2019) 17:507–21. doi:10.1111/vco.12514

55. Kareva I, Waxman DJ, Lakla Klement G. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. (2015) 358:100–6. doi:10.1016/j.canlet.2014.12.039

56. Hahn K, Richardson R, Acvim D, Knapp D. Canine malignant mammary neoplasia: biological behavior, diagnosis, and treatment alternatives. J Am Anim Hosp Assoc. (1992) 28:251.

57. Oglivie GK, Reynolds HA, Richardson RC, Withrow SJ, Norris AM, Henderson RA, et al. Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc. (1989) 195:1580–3.

58. Zambrano-Estrada X, Landaverde-Quiroz B, Dueñas-Bocanegra AA, De Paz-Campos MA, Hernández-Alberto G, Solorio-Perusquia B, et al. Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer. BMC Vet Res. (2018) 14:87. doi:10.1186/s12917-018-1411-6

59. Sorensen K. Canine mammary gland tumors. Vet Clin North Am Small Anim Pract. (2003) 33:573–96. doi:10.1016/S0301-5616(03)00020-2

60. Hahn K, Richardson R, Acvim D, Knapp D. Canine malignant mammary neoplasia: biological behavior, diagnosis, and treatment alternatives. J Am Anim Hosp Assoc. (1992) 28:251.
dose chemotherapy in dogs with osteosarcoma. *J Small Anim Pract.* (2014) 55:369–74. doi: 10.1111/jasp.12228

74. London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, et al. Impact of toceranib/piroxicam/cyclophosphamide maintenance therapy on outcome of dogs with appendicular osteosarcoma following amputation and carboplatin chemotherapy: a multi-institutional study. *PLOS ONE.* (2015) 10:e0124889. doi: 10.1371/journal.pone.0124889

75. Duffy ME, Anderson CL, Choy K, Fidel JL. Metronomic administration of lomustine following palliative radiation therapy for appendicular osteosarcoma in dogs. *Can Vet J.* (2018) 59:136–42.

76. Matsuyama A, Schott CR, Wood GA, Richardson D, Woods JP, Mutsaers AJ. Evaluation of metronomic cyclophosphamide chemotherapy as maintenance treatment for dogs with appendicular osteosarcoma following limb amputation and carboplatin chemotherapy. *J Am Vet Med Assoc.* (2018) 252:1377–83. doi: 10.2460/javma.252.11.1377

77. Morgan E, O’Connell K, Thomson M, Boyd S, Sandy J. Primary hepatic neuroendocrine carcinoma treated with doxorubicin and cyclophosphamide in a dog. *J Am Anim Hosp Assoc.* (2019) 55:e55305. doi: 10.3326/IAAHA-MS-6887

78. Polton G, Finetello R, Sabattini S, Rossi F, Laganga P, Vasconi ME, et al. Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide. *Vet Comp Oncol.* (2018) 16:399–408. doi: 10.1111/vco.12393

79. Elmslie RE, Glawe P, Dow SW. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. *J Vet Intern Med.* (2008) 22:1373–9. doi: 10.1111/j.1939-1676.2008.0179.x

80. Burton JH, Mitchell L, Thamm DH, Dow SW, Biler BJ. Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. *J Vet Intern Med.* (2011) 25:920–6. doi: 10.1111/j.1939-1676.2011.0753.x

81. Leach TN, Childress MO, Greene SN, Mohamed AS, Moore GE, Schrempf DR, et al. Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer. *Vet Comp Oncol.* (2012) 10:102–12. doi: 10.1111/j.1749-727X.2011.01320.x

82. Cancedda S, Marconato L, Meier V, Laganga P, Roos M, Leone VF, et al. Hypofractionated radiotherapy for macroscopic canine soft tissue sarcoma: a retrospective study of 50 cases treated with a 5 x 6 Gy protocol with or without metronomic chemotherapy. *Vet Radiol Ultrason.* (2016) 57:75–83. doi: 10.1111/vru.12108

83. Schrempf DR, Childress MO, Stewart JC, Leach TN, Tan KM, Abbo AH, et al. Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma. *J Am Vet Med Assoc.* (2013) 242:1534–8. doi: 10.2460/javma.242.11.1534

84. Campos CBDE, Lavalle GE, Monteiro LN, Pérgas GGA, Filho SL, Balbaram D. Adjuvant thalidomide and metronomic chemotherapy for the treatment of canine malignant mammary gland neoplasms. *In Vivo.* (2018) 32:1659–66. doi: 10.21873/invivo.11429

85. Rossi F, Sabattini S, Vascelli M, Marconato L. The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma. *Vet Comp Oncol.* (2018) 16:497–504. doi: 10.1111/vco.12407

86. Masoud V, Pagès G. Targeted therapies in breast cancer: new challenges to fight against resistance. *World J Clin Oncol.* (2017) 8:120. doi: 10.5306/wjco.v8.i8.120

87. Schneider R, Dorn CR, Taylor DO. Factors influencing canine mammary cancer development and postsurgical survival. *J Natl Cancer Inst.* (1969) 43:1249–61.

88. Misadrop W. Canine mammary tumours: protective effect of late ovariectomy and stimulating effect of progestins. *Acta Vet Scand.* (1969) 52:67. doi: 10.1186/1751-0147-52-67

89. Meng Q, Yuan F, Goldberg ID, Rosen EM, Auborn K, Fan S. Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. *Endocr Relat Cancer.* (2018) 25:263–153. doi: 10.1103/ERC-11-0378

90. Martiní-Ruiz A, Peña L, González-Gil A, Díez-Córdova LT, Cáceres S, Illera JC. Effects of indole-3-carbinol on steroid hormone profile and tumor progression in a mice model of canine inflammatory mammary carcinoma. *BMC Cancer.* (2018) 18:626. doi: 10.1186/s12885-018-4518-z

91. Trentom A, Lu J, Cole JT. Endocrine therapy for early breast cancer: updated review. *Oxshofer J.* (2017) 17:805–11.

92. Suzuki T, Moriya T, Ishida T, Ohuchi N, Sasano H. Intracellular mechanism of estrogen synthesis in breast cancer. *Biomed Pharmacother.* (2003) 57:460–2. doi: 10.1016/j.biopha.2003.09.007

93. De Andres PJ, Caceres S, Clemente M, Perez-Alenza MD, Illera JC, Pena L. Profile of steroid receptors and increased aromatase immunoeexpression in canine inflammatory mammary cancer as a potential therapeutic target. *Reprod Domest Anim.* (2016) 51:269–75. doi: 10.1111/rdad.12676

94. Brainard GC, Hanifin JP, Greeson JM, Byrne B, Glickman G, Gerner E, et al. Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. *J Neurosci.* (2001) 21:6405–12. doi: 10.1523/JNEUROSCI.21-16-06405.2001

95. Brydon L, Roka F, Petit L, de Crippé P, Tissot M, Barrett P, et al. Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. *Mel Endocrinol.* (1999) 13:2203–9. doi: 10.1210/jpi.13.2203

96. Jablonska K, Pula B, Zemla A, Owczarek T, Wojnar A, Rys J, et al. Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma. *J Pineal Res.* (2013) 54:334–45. doi: 10.1111/j.1750-3940.2013.01224.x

97. Kupsch M, Campa C, González A, Mediavilla MD, Alonso-González C, Álvarez-García V, Sánchez-Barceló EJ, et al. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. *Br J Cancer.* (2009) 101:1613–19. doi: 10.1038/sj.bjc.6605336
111. Blask DE, Hill SM, Dauchy RT, Xiang S, Yuan L, Duplessis T, et al. Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. J Pineal Res. (2011) 51:559–69. doi: 10.1111/j.1600-079X.2011.00888.x

112. Dorgan JE, Longcope C, Stephenson HE Jr, Falk RT, Miller R, Franz C, et al. Serum sex hormone levels are related to breast cancer risk in postmenopausal women. Environ Health Perspect. (1997) 105(Suppl 3):583–5. doi: 10.1289/ehp.97105S383

113. Gonzalez LO, Corte MD, Vazquez J, Junquera S, Sanchez R, Alvarez AC, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteinases and their inhibitors. BMC Cancer. (2008) 8:149. doi: 10.1186/1471-2407-8-149

114. Esfahani RJ, Zarghami N, Esfahani AJ, Mollahadieh M, Nejati K, Nasiri M. The possible impact of obesity on androgen, progesterone and estrogen receptors (ERα and ERβ) gene expression in breast cancer patients. Breast Cancer. (2011) 5:227–37. doi: 10.4137/BCBR.57707

115. Kono M, Fuji T, Lim B, Karuturi MS, Tripathy D, Ueno NT. Androgen receptor function and androgen receptor-targeted therapies in breast cancer: a review. JAMA Oncol. (2017) 3:1266–73. doi: 10.1001/jamaoncol.2016.4975

116. Ji YK, Lee GS, Choi KC, Jeung EB. Anti-progestogenic effect of flutamide on uterine expression of calbindin-D9k mRNA and protein in immature mice. Reprod Toxicol. (2006) 22:694–701. doi: 10.1016/j.reprotox.2006.04.015

117. Frank D, Sharpe N, Scott MC, Mirro E, Hartman B, Hallwill WH. Chronic effects of flutamide in male beagle dogs. Toxicol Pathol. (2004) 32:242–9. doi: 10.1093/toxicalpathology/32.4.242

118. Caceres S, Monsalve B, Peña L, de Andres PJ, Alonso-Diez A, Illera MJ, et al. In vitro and in vivo effect of flutamide on steroid hormone secretion in canines and human inflammatory breast cancer cell lines. Vet Comp Oncol. (2018) 16:148–8. doi: 10.1111/vco.12324

119. McGuire WL, Horwitz KB. A role for progesterone in breast cancer. Ann NY Acad Sci. (1977) 286:90–100. doi: 10.1111/j.1749-6632.1977.tb9408.x

120. Timmermans-Sprang EPM, Gracanin A, Mol JA. Molecular signaling of progesterone receptor function and androgen receptor-targeted therapies in breast cancer: past, present, future. J Mol Endocrinol. (2020) 65:49–63. doi: 10.1530/JME-20-0104

121. Huber JC, Ott J. The dialectic role of progesterone. Maturitas. (2009) 62:326–9. doi: 10.1016/j.maturitas.2008.12.009

122. Kariagina A, Apupperlee MD, Haslam SZ. Progesterone receptor isoform functions in normal breast development and breast cancer. Crit Rev Eukaryotic Gene Exp. (2018) 18:11–33. doi: 10.1615/CritRevEukaryoticGeneExp.v8i11.20

123. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, et al. Progesterone receptor expression in breast cancer: a comprehensive analysis of ERα and ERβ expression in breast cancer patients. Histol Histopathol. (2010) 25:518–23. doi: 10.1111/j.1365-2559.2010.03723.x

124. Gosling LO, Corte MD, Vazquez J, Junquera S, Sanchez R, Alvarez AC, et al. Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human mammary cancer cells following surgical excision. J Mol Endocrinol. (2021) 15:3856–65. doi: 10.1530/JME-20-01077

125. Karapetiants M, Krasniqi E, Barchiesi G, Pizzuti L, Tomao F, Barba M, et al. Pharmacological modulation of metalloproteases and their inhibitors. BMC Cancer. (2014) 14:53. doi: 10.1186/1471-2407-14-53

126. Hermo GA, Turic E, Angelico D, Scorsoni AM, Gomez DE, Gobello C, et al. Effect of adjuvant perioperative desmopressin in locally advanced canine mammary carcinoma and its relation to histologic grade. J Am Anim Hosp Assoc. (2011) 47:21–7. doi: 10.3366/VAHA-MS-5509

127. Weinberg RS, Grecco MO, Ferro GS, Seigelshifer DJ, Perroni NV, Terrier FJ, et al. A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-D-arginine vasopressin) in breast cancer patients. Springerplus. (2015) 4:428. doi: 10.1186/s40064-015-1217-7

128. Sorenmo K, Durham AC, Evans B, Scavello H, Stefanovski D. A prospective randomized trial of desmopressin in canine mammary carcinoma. Vet Comp Oncol. (2010) 18:796–803. doi: 10.1111/j.1200-624X.2010.00129.x

129. Link W. Principles of Cancer Treatment and Anticancer Drug Development. Cham: Springer International Publishing (2019). doi: 10.1007/978-3-030-18722-4

130. Berryhofer P, Kunert R. Nomenclature of humanized mAbs: early concepts, current challenges and future perspectives. Hum Antibodies. (2019) 27:37–51. doi: 10.3333/HAB.180347

131. Randieri PV, Mancini MF, Schiavoni G, Pizzuti L, Tomao F, Barba M, et al. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review. Crit Rev Oncol Hematol. (2013) 88:293–308. doi: 10.1016/j.critrevonc.2013.05.009

132. Papapetis GS, Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs. (2009) 23:577–81. doi: 10.1007/s40242-010-00038-w

133. Mazzotta M, Krasniqi E, Barchiesi G, Pizzuti L, Tomao F, Barba M, et al. Long-term safety and real-world effectiveness of trastuzumab in breast cancer. J Clin Med. (2019) 8:254. doi: 10.3390/jcm8020254
154. Graham JC, Myers RK. The prognostic significance of angiogenesis.

155. Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Petrovic N. Targeting angiogenesis in cancer treatments: where do we stand?

157. Ribatti D, Nico B, Ruggieri S, Tamma R, Simone G, Mangia A. Angiogenesis.

160. Ranieri G, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, et al. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. (2020) 17:233–50. doi: 10.1038/s41571-019-0299-9

163. Slamon D, Gomez HL, Kabbinavar FF, Amit O, Richie M, Pandite L, et al. Raf kinase as a target for sorafenib in canine mammary gland tumors.

165. Sridhar SS, Hedley D, Siu LL. Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis. (2020) 23:55–74. doi: 10.1007/s10456-019-09698-6

166. Mangini Prado MC, Losant Macedo SDA, Gumiero Guiraldelli G, Lainetti

167. Lee JH, Li Q, An JH, Yang XY, Qiu WW, Liu GL. Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res. (2012) 31:16. doi: 10.1186/1756-9966-31-16

168. Kennedy KC, Qurollo BA, Rose BJ, Thamm DH. Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines. Vet Comp Oncol. (2011) 9:196–206. doi: 10.1111/j.1476-5829.2010.00248.x

169. Kennedy KC, Qurollo BA, Rose BJ, Thamm DH. Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines. Vet Comp Oncol. (2011) 9:196–206. doi: 10.1111/j.1476-5829.2010.00248.x

170. Folberg R, Hendrix MJ, Maniotis AJ. Vascular mimicry and tumor angiogenesis. Am J Pathol. (1999) 155:739–52. doi: 10.1016/S0002-9440(99)65173-5

171. Bajna E, et al. Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol Immunol. (2012) 50:200–9. doi: 10.1016/j.molimm.2012.01.002

172. Kuczynski EA, Reynolds AR. Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis. (2020) 23:55–74. doi: 10.1007/s10456-019-09698-6

173. Liu Q, Yan H, Zhao P, Yang Y, Cao B. Efficacy of safety of bevacizumab combined with chemotherapy for managing metastatic breast cancer: a meta-analysis of randomized controlled trials. Sci Rep. (2015) 5:15746. doi: 10.1038/srep15746

174. Pinto MP, Sotomayor P, Carrasco-Avino G, Corvalan AH, Owen GI. Escaping antiangiogenic therapy: strategies employed by cancer cells. Int J Mol Sci. (2016) 17:1489. doi: 10.3390/ijms17091489

175. Folberg R, Maniotis AJ. Vascular mimicry.

176. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry.

177. Zhang J, Qiao L, Liang N, Xie J, Luo H, Deng G. Vasculogenic mimicry and angiogenesis.

178. Kuczynski EA, Vermeulen PB, Pezzella F, Kerbel RS, Reynolds AR.

179. Kuczynski EA, Vermeulen PB, Pezzella F, Kerbel RS, Reynolds AR. Vessel co-option in cancer. Nat Rev Clin Oncol. (2019) 16:469–93. doi: 10.1038/s41571-019-0181-9

180. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol. (1999) 31:1037–51. doi: 10.1016/S1357-2725(99)00076-X

181. Abbaspour Babaei M, Kamalidehghan B, Saleem M, Hurí HZ, Ahmadpour F. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des Dev Ther. (2016) 10:2443–59. doi: 10.2147/DDDT.S89114

182. Kupel M, Webster JD, Kanean JB, Miller R, Yuzbasiyan-Gurkan V. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Vet Pathol. (2004) 41:371–7. doi: 10.1354/vp.41-4-371

183. Janostik R, Vyas M, Ciccek AF, Wajapayee N, Harigopal M. Loss of c-KIT expression in breast cancer correlates with malignant transformation of breast epithium and is mediated by KIT gene promoter DNA hypermethylation. Exp Mol Pathol. (2018) 105:41–9. doi: 10.1016/j.yexmp.2018.05.011

184. Gattino F, Maniscalco L, Iussich S, Biasato I, Martano M, Morello E, et al. PDGFR-α, PDGFR-β, VEGFR-2 and CD117 expression in canine mammary tumours and evaluation of the in vitro effects of tocotrienol phosphate in neoplastic mammary cell lines. Vet Rec. (2018) 183:221. doi: 10.1136/vr.104414

185. Kubo K, Matsuyma S, Katayama K, Tsutsumi C, Yonezawa K, Kamiya K, et al. S-phase cell cycle arrest in canine mammary gland tumor cell lines. Vet Pathol. (2010) 47:265–74. doi: 10.1177/0300985809353167

186. Kennedy KC, Qurollo BA, Rose BJ, Thamm DH. Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines. Vet Comp Oncol. (2011) 9:196–206. doi: 10.1111/j.1476-5829.2010.00248.x

187. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. (1999) 155:739–52. doi: 10.1016/S0002-9440(99)65173-5

188. Folberg R, Hendrix MJ, Maniotis AJ. Vascular mimicry and tumor angiogenesis. Am J Pathol. (2000) 156:361–81. doi: 10.1006/ajpath.2000.1281

189. Holash J, Maisonnepier PC, Compton D, Boland P, Alexander CR, Zaggag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. (1999) 284:1994–8. doi: 10.1126/science.284.5222.1994

190. Kuczynski EA, Reynolds AR. Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis. (2020) 23:55–74. doi: 10.1007/s10456-019-09698-6

191. Xu Y, Li Q, Li XY, Yang XY, Qiu WW, Liu GL. Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res. (2012) 31:16. doi: 10.1186/1756-9966-31-16

192. Koczara A, Miller K, Helmke M, Grossmann S, Alken P, Stroh T, et al. Antiangiogenic therapy in cancer: from the biology to the clinic. Nat Rev Clin Oncol. (2019) 16:469–93. doi: 10.1038/s41571-019-0181-9

193. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol. (1999) 31:1037–51. doi: 10.1016/S1357-2725(99)00076-X

194. Abbaspour Babaei M, Kamalidehghan B, Saleem M, Hurí HZ, Ahmadpour F. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des Dev Ther. (2016) 10:2443–59. doi: 10.2147/DDDT.S89114

195. Kupel M, Webster JD, Kanean JB, Miller R, Yuzbasiyan-Gurkan V. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Vet Pathol. (2004) 41:371–7. doi: 10.1354/vp.41-4-371

196. Kennedy KC, Qurollo BA, Rose BJ, Thamm DH. Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines. Vet Comp Oncol. (2011) 9:196–206. doi: 10.1111/j.1476-5829.2010.00248.x

197. Folberg R, Hendrix MJ, Maniotis AJ. Vascular mimicry and tumor angiogenesis. Am J Pathol. (2000) 156:361–81. doi: 10.1006/ajpath.2000.1281
toward increased reproducibility. *Int J Gynecol Pathol.* (2019) 38(Suppl. 1):S123–31. doi: 10.1097/PGP.0000000000000488

206. Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, et al. Distinct tumor protein p53 mutants in breast cancer subgroups. *Int J Cancer.* (2013) 132:1227–31. doi: 10.1002/ijc.27767

207. Pan Y, Yuan Y, Liu G, Wei Y, PS3 and Ki-67 as prognostic markers in triple-negative breast cancer patients. *PLoS ONE.* (2017) 12:e0172324. doi: 10.1371/journal.pone.0172324

208. Abubakar M, Guo C, Koka H, Sung H, Shao N, Guida J, et al. Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical staining. *NPJ Breast Cancer.* (2019) 5:20. doi: 10.1038/s41523-019-0117-7

209. Fabi A, Mottolese M, Di Benedetto A, Sperati F, Ercolani C, Buglioni S, et al. p53 and BCL2 immunohistochemical expression across molecular subtypes in 1099 early breast cancer patients with long-term follow-up: an observational study. *Clin Breast Cancer.* (2020) 20:766–70. doi: 10.1016/j.cbc.2020.05.005

210. Morris JS, Nixon C, King OJ, Morgan IM, Philibey AW. Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53. *Vet J.* (2009) 179:422–9. doi: 10.1016/j.tvjl.2007.10.025

211. Rodo A, Malicka E. Immunohistochemical expression of protein p53 in neoplasms of the mammary gland in bitches. *Pol J Vet Sci.* (2008) 11:89–95.

212. Lee CH, Kim WH, Lim JH, Kang MS, Kim DY, Kweon OK. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. *Vet Sci.* (2014) 1:563–9. doi: 10.3390/vetsci1043.1.6.3

213. Levine AL. Targeting therapies for the p53 protein in cancer treatments. *Ann Rev Cancer Biol.* (2019) 3:21–34. doi: 10.1146/annurev-cancerbio-030518-055455

214. Zhou X, Hao Q, Lu H. Mutant p53 in cancer therapy—the barrier or the path. *J Mol Cell Biol.* (2019) 11:293–305. doi: 10.1093/mcbj/mjy072

215. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and tumor progression. *J Am Coll Surg.* (2002) 126:456–8. doi: 10.1016/S1072-7391(01)01512-5

216. Munday JS, Ariyarathna H, Aberdein D, Thomson NA. Immunostaining of p53 in canine mammary carcinomas. *J Comp Pathol.* (2014) 151:202–6. doi: 10.1016/j.jcpa.2014.04.018

217. Carvalho MI, Fares I, Dias M, Prada J, Gregório H, Lobo L, et al. Intratumoral CD3+ T-lymphocytes immunomodulation and its association with c-Kit, angiogenesis, and overall survival in malignant canine mammary tumors. *Anat Cell Pathol.* (2015) 2015:920409. doi: 10.1155/2015/920409

218. London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, de Campos CB, Lavalle GE, Fialho Ligório S, Camargo Nunes F, Carneiro R. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. *Clin Cancer Res.* (2003) 9:2755–68.

219. de Campos CB, Lavalle GE, Fialho Ligório S, Camargo Nunes F, Carneiro RA, Amorim RL, et al. Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas. *Vet Rec.* (2016) 179:514. doi: 10.1136/vetrecr.2013764

220. Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. *Vet Intern Med.* (2008) 22:1301–9. doi: 10.1111/j.1939-1676.2008.01910.x

221. Thamm DH, Rose B, Kow K, Humbert M, Mansfield CD, Moussy A, et al. Masitinib is a chemosensitizer of canine tumor cell lines: a proof of concept study. *Vet J.* (2012) 191:131–4. doi: 10.1016/j.tvjl.2011.01.001

222. Clark AS, Karasic TB, DeMichele A, Vaughan DJ, O’Hara M, Perini R, et al. Palbociclib (PD0332991)-a selective and potent cyclin-dependent kinase inhibitor: a review of pharmacodynamics and clinical development. *JAMA Oncol.* (2016) 2:253–60. doi: 10.1001/jamaoncol.2015.4701

223. Arun B, Goss P. The role of COX-2 inhibition in breast tumorigenesis, but how? *Clin Cancer Res.* (2002) 87:91–6.

224. Abdelmegeed SM, Mohammed S. Canine mammary tumors as a model for human cancers: origins, consequences, and clinical use. *Cold Spring Harb Perspect Biol.* (2010) 2:a001008. doi: 10.1101/cshperspect.a001008

225. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events with long-term use of aspirin: meta-analysis. *JAMA.* (2008) 300:152820. doi: 10.1001/jama.2008.152820

226. Szweda M, Rychlik A, Babinska I, Pionkowska O. Significance of cyclooxygenase-2 in oncogenesis. *J Vet Res.* (2013) 5:63–9. doi: 10.4142/jvs.2004.5.1.63

227. Pol J Vet Sci. (2019) 20:e760–70. doi: 10.1371/journal.pone.0172324

228. Ueda T, Harada N, Katsura M, Koganezawa H, Abe O, Shimizu T, et al. Immunohistochemical expression of protein p53 in canine mammary carcinomas. *Vet Comp Oncol.* (2017) 15:451–65. doi: 10.1111/vco.12289

229. Jurka P. Diagnostic efficacy of smear cytology and robinson's cytological practice. *Vet J.* (2018) 204:488–94. doi: 10.3892/ov.2018.6409

230. Abdelmegeed SM, Mohammed S. Canine mammary tumors as a model for human disease. *Vet Lett.* (2018) 18:5195–205. doi: 10.3892/ol.2018.8411

231. Oliveira TF, Maués T, Ramundo MS, Figueiredo AMS, de Mello MFV, de Mello POA, et al. Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas. *Vet Rec.* (2016) 179:514. doi: 10.1136/vetrecr.2013764

232. Bartley AN, Ross DW. Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice. *Arch Pathol Lab Med.* (2002) 126:456–8. doi: 10.1043/0003-9985(2002)126<0456:VOPLAA>2.0.CO;2

233. Kempel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 immunohistochemistry in endometrial carcinomas. *Frontiers in Veterinary Science* | www.frontiersin.org 27 February 2021 | Volume 8 | Article 623800
226. White WB, West CR, Borger JS, Gorelick PB, Lavange L, Pan SX, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. (2007) 99:91–8. doi: 10.1016/j.amjcard.2006.07.069

227. Li S, Jiang M, Wang L, Yu S. Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: recent advancement. Biomed Pharmacother. (2020) 129:110389. doi: 10.1016/j.biopha.2020.110389

228. Dore M. Cyclooxygenase-2 expression in animal cancers. Vet Pathol. (2011) 48:254–65. doi: 10.1177/0300985810379434

229. Dore M, Lanthier I, Sirois J. Cyclooxygenase-2 expression in canine mammary tumours. Vet Pathol. (2003) 40:207–12. doi: 10.1354/vp-40-2-207

230. Badowska-Kozakiewicz AM, Malicka E. Expression of cyclooxygenase-2 in neoplasms of the mammary gland in bitches. Pol J Vet Sci. (2010) 13:337–42.

231. Guimaraes MJ, Carvalho MI, Pires I, Prada J, Gil AG, Lopes C, et al. Concurrent expression of cyclooxygenase-2 and epidermal growth factor receptor in canine malignant mammary tumours. J Comp Pathol. (2014) 150:27–34. doi: 10.1016/j.jcpa.2013.07.005

232. Millanta F, Asproni P, Canale A, Citi S, Poli A. COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours. Vet Comp Oncol. (2016) 14:270–80. doi: 10.1111/vco.12096

233. Queiroga FL, Pires I, Parente M, Gregório H, Lopes CS. COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary cancer. Vet J. (2011) 189:77–82. doi: 10.1016/j.tvjl.2010.06.022

234. Clemente M, Sanchez-Archidona AR, Sardon D, Díez L, Martín-Ruiz A, Caceres S, et al. Different role of COX-2 and angiogenesis in canine inflammatory and non-inflammatory mammary cancer. Vet J. (2013) 197:427–32. doi: 10.1016/j.tvjl.2013.02.009

235. Carvalho MI, Pires I, Prada J, Raposo TP, Gregório H, Lobo L, et al. High cyclooxygenase-2 expression correlates with VEGF and tumour angiogenesis in canine mammary tumour cell line, CMT-U27. Vet J. (2011) 203: doi: 10.4161/cam.4.2.10943

236. Corso G, Figueiredo J, De Angelis SP, Corso F, Girardi A, Pereira J, et al. E-cadherin deregulation in breast cancer. J Cell Mol Med. (2020) 24:9390–6. doi: 10.1111/jcm.15140

237. Li Z, Yin S, Zhang L, Liu W, Chen B. Prognostic value of reduced E-cadherin expression in breast cancer: a meta-analysis. Oncotarget. (2017) 8:16445–55. doi: 10.18632/oncotarget.14860

238. Matos AJ, Lopes C, Carvalheira J, Santos M, Rutteman GR, Gartner F. E-cadherin expression in canine malignant mammary tumours: relationship to other clinicopathological variables. J Comp Pathol. (2006) 134:182–9. doi: 10.1016/j.jcpa.2005.10.004

239. Brunetti B, Sarli G, Preziosi R, Leprotti S, Benazzi C. E-cadherin expression in canine mammary carcinomas with regional lymph node metastases. J Vet Med A Physiol Pathol Clin Med. (2003) 50:496–500. doi: 10.1111/j.1439-0442.2003.00577.x

240. Brunetti B, Sarli G, Preziosi R, Monari I, Benazzi C. E-cadherin and beta-catenin reduction influence invasion but not proliferation and survival in canine malignant mammary tumours. Vet Pathol. (2005) 42:781–7. doi: 10.1354/vp-42-6-781

241. De Matos AJ, Lopes CC, Faustino AM, Carvalheira JG, Rutteman GR, Gartner Mde F. E-cadherin, beta-catenin, invasion and lymph node metastases in canine malignant mammary tumours. Apmixs. (2007) 115:327–34. doi: 10.1111/j.1600-0463.2007.apmix_344.x

242. Asproni P, Ressel I, Millanta F, Vannozzi I, Poli A. Co-localization of PTEN and E-cadherin in canine mammary hyperplasias and benign and malignant mammary tumours. Res Vet Sci. (2015) 103:113–18. doi: 10.1016/j.rvsc.2015.09.022

243. Gama A, Paredes J, Gartner F, Alves A, Schmitt F. Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival. Vet J. (2008) 177:45–53. doi: 10.1016/j.tvjl.2007.05.024

244. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. (2009) 119:1420–8. doi: 10.1172/JCI39104

245. Wu Y, Zhou BP. Snail: more than EMT. Cell Adhesion Migr. (2010) 4:199–283. doi: 10.4161/cam.4.2.10943

246. Gamba CO, Rodrigues MA, Gomes DA, Estrela-Lima A, Ferreira E, Cassali GD. The relationship between E-cadherin and its transcriptional repressors in spontaneously arising canine invasive micropapillary mammary carcinoma. J Comp Pathol. (2015) 153:256–65. doi: 10.1016/j.jcpa.2015.08.006

247. Gamba CO, Damasceno KA, Ferreira IC, Rodrigues MA, Gomes DA, Alves MR, et al. The investigation of transcriptional repression mediated by ZEB2 in canine invasive micropapillary carcinoma in mammary gland. PLoS ONE. (2019) 14:e0209497. doi: 10.1371/journal.pone.0209497

248. Schatton T, Frank-NY, Frank MH. Identification and targeting of cancer stem cells. Bioessays. (2009) 31:1038–49. doi: 10.1002/bies.200990038

249. Morel A-P, Lièvre M, Thomas C, Hinkel G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE. (2008) 3:e2888. doi: 10.1371/journal.pone.002888

250. Gooding AJ, Schiemen WP. Epithelial-mesenchymal transition programs and cancer stem cell phenotypes: mediators of breast cancer therapy resistance. Mol Cancer Res. (2020) 18:1257–70. doi: 10.1158/1541-7786.MCR-20-0067

251. Sun X, Wang M, Yao L, Li X, Dong H, Li M, et al. Exploring the metabolic vulnerabilities of epithelial-mesenchymal transition in breast cancer. Front Cell Dev Biol. (2020) 8:665. doi: 10.3389/fcell.2020.00665

252. Kong D, Hughes CJ, Ford HL. Cellular plasticity in breast cancer progression and therapy. Front Mol Biosci. (2020) 7:72. doi: 10.3389/fmolb.2020.00072

253. Raspoc-Ferreira TMM, Brisson BK, Durham AC, Laufer-Amorim R, Sousa CM, Boaes JC, et al. Bioessays. (2009) 31:1038–49. doi: 10.1002/bies.200990038
284. Ko YS, Lee WS, Panchanathan R, Joo YN, Choi YH, Kim GS, et al. Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle. (2010) 9:4461–8. doi: 10.4166/cc.9.22.14048

285. Pirali M, Taheri M, Zarei S, Majidi M, Ghafoori H. Artesunate, as a HSP70 ATPase activity inhibitor, induces apoptosis in breast cancer cells. Int J Biol Macromol. (2020) 164:369–73. doi: 10.1016/j.ijbiomac.2020.08.198

286. Dong J, Yang W, Han J, Cheng R, Guo X, Li L. Effect of dihydroartemisinin on epithelial-to-mesenchymal transition in canine mammary tumour cells. Res Vet Sci. (2019) 124:240–7. doi: 10.1016/j.rvsc.2019.03.020

287. von Hagens C, Walter-Sack I, Goeckenjan M, Storch-Hagenlocher B, Sertel S, Elsässer M, et al. Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2). Phytomedicine. (2019) 54:140–8. doi: 10.1016/j.phymed.2018.09.178

288. Dow S. A role for dogs in advancing cancer immunotherapy research. Front Immunol. (2018) 9:312. doi: 10.3389/fimmu.2018.00312

289. Bock BC, Stein U, Schmitt CA, Augustin HG. Mouse models of human breast cancer. J Immunol. (2004) 172:2731–8. doi: 10.4049/jimmunol.172.2.2731

290. Belcheva I, Vahsen TM. Hybrid-cell vaccines for cancer immune therapy. Crit Rev Immunol. (2015) 35:239–58. doi: 10.1080/02716762.2015.1026793

291. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. (2004) 172:2731–8. doi: 10.4049/jimmunol.172.2.2731

292. Kopezt P, Lemos R, Powiś G. The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res. (2018) 19:421–2. doi: 10.1158/1078-0432.CCR-17-1090

293. Bock BC, Stein U, Schmitt CA, Augustin HG. Mouse models of human breast cancer. J Immunol. (2004) 172:2731–8. doi: 10.4049/jimmunol.172.2.2731

294. Feng Y, Zhang Y, Sun Q, Zhao H, Xu J, Wang R, et al. Anti-tumour effect of metformin in canine mammary gland tumour cells. Vet J. (2019) 255:297–304. doi: 10.1016/j.tvjl.2019.04.026

295. Panossian LA, Garga NI, Pelletier D. Toxic brainstem encephalopathy after artesunate treatment in primary culture of canine mammary tumors. Oncol Lett. (2015) 9:1313–7. doi: 10.3892/ol.2015.3849

296. Park JS, Withers SS, Modiano JF, Kent MS, Chen M, Luna JJ, et al. Canine cancer immunotherapy: current modalities in cancer immunotherapy: immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther. (2017) 178:34–51. doi: 10.1016/j.pharmthera.2017.03.008

297. Kim R, Emi M, Tanabe K. Cancer immunoeediting from immune surveillance to immune escape. Immunology. (2007) 121:1–14. doi: 10.1111/j.1365-2667.2007.02587.x

298. Dow S. A role for dogs in advancing cancer immunotherapy research. Front Immunol. (2018) 9:312. doi: 10.3389/fimmu.2018.00312

299. Wang Q, Wu X. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. J Immunother. (2014) 37:467–8. doi: 10.1002/1078-0432.CCR-12-2408

300. Bock BC, Stein U, Schmitt CA, Augustin HG. Mouse models of human breast cancer. J Immunol. (2004) 172:2731–8. doi: 10.4049/jimmunol.172.2.2731

301. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. (2004) 172:2731–8. doi: 10.4049/jimmunol.172.2.2731

302. Kopezt P, Lemos R, Powiś G. The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res. (2018) 19:421–2. doi: 10.1158/1078-0432.CCR-17-1090

303. Dow S. A role for dogs in advancing cancer immunotherapy research. Front Immunol. (2020) 10. doi: 10.3389/fimmu.2019.02935

304. Regan D, Dow S. Manipulation of innate immunity for cancer therapy in dogs. Vet Sci. (2015) 2:423–39. doi: 10.3390/vetsci2004023

305. Park JS, Withers SS, Modiano JF, Kent MS, Chen M, Luna JJ, et al. Canine cancer immunotherapy: linking mouse and human. J Immunother Cancer. (2016) 4:87. doi: 10.1002/1078-0432.CCR-12-2408

306. Me Finocchiaro L, Glikin G. Recent clinical trials of cancer immunogene therapy in companion animals. World J Exp Med. (2017) 7:42–8. doi: 10.5493/wjem.v7.i2.42
Therapies in Canine Mammary Cancer

Valdivia et al.

profiling analysis fitted boolean models. *Bioengineered*. (2019) 10:199–6. doi: 10.1080/21655797.2019.1622220

348. Igase M, Shousu K, Fujiki N, Sakurai M, Bonkobara M, Hwang CC, et al. Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells. *Vet Comp Oncol*. (2019) 17:184–93. doi: 10.1111/vco.12468

349. Hamada K, Takagi S, Kuboshima H, Shimada H, Takagi K, Yasuoka T, et al. Cloning of carrier cells infected with oncolytic adenovirus driven by midkine promoter and biosafety studies. *J Gen Med*. (2019) 21:e0364. doi: 10.1002/jgm.3064

350. Zygiert Z, Hodgkin's disease: remissions after measles. *Lancet*. (1971) 1:593. doi: 10.1016/S0140-6736(71)91186-X

352. Delpeut S, Sisson G, Black KM, Richardson CD. Measles virus enters breast and colon cancer cell lines through a PVRL4-mediated macropinocytosis pathway. *J Virol*. (2017) 91:e02919-16. doi: 10.1128/JVI.02919-16

353. Táí CJ, Liu CH, Pan YC, Wong SH, Richardson CD, Lin LT. Chemovirotreatment therapy using camptothecin enhances oncolytic measles virus-mediated killing of breast cancer cells. *Sci Rep*. (2019) 9:6767. doi: 10.1038/s41598-019-43047-3

354. Abdullah SA, Al-Shammari AM, Lateef SA. Attenuated measles virus vaccine strain have potent oncolytic activity against Iraqi patient derived breast cancer cell line. *Saudi J Biol Sci*. (2020) 27:865–72. doi: 10.1016/j.sjbs.2020.12.015

356. Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, Donat H, et al. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. *Cancer Gene Ther*. (2009) 16:320–8. doi: 10.1038/cgt.2008.87

357. Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, et al. Significant growth inhibition of canine mammary carcinoma xenografts following treatment with oncolytic vaccinia virus GLV-1h68. *J Oncol*. (2010) 2010:736907. doi: 10.1155/2010/736907

358. Urgaç AS, Hynes S, Somarak A, Contakos S, Rahman MM, Liu J, et al. Oncolysis of canine tumor cells by myxoma virus lacking the serp2 gene. *Am J Vet Res*. (2012) 73:1252–61. doi: 10.2460/ajvr.73.8.1252

359. Rodriguez Stewart RM, Berry JT, Berger AK, Yoon SB, Hirsch AL, Guberman JA, et al. Enhanced killing of triple-negative breast cancer cells by reasortant reovirus and topoisomerase inhibitors. *J Virol*. (2019) 93:e01411-19. doi: 10.1128/JVI.01411-19

361. De Jong WH, Borm PJA. Drug delivery and nanoparticles-applications and hazards. *Int J Nanomed*. (2008) 3:33–49. doi: 10.2147/IJN.S596

362. Zochi MR, Tosetti F, Benelli R, Poggi A. Cancer nanomedicine special issue review anticanter drug delivery with nanoparticles: extracellular vesicles or synthetic nanobeads as therapeutic tools for conventional treatment or immunotherapy. *Cancers*. (2020) 12:1886. doi: 10.3390/cancers12071886

363. Mirza Z, Karim S. Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges. *Semin Cancer Biol*. (2019). doi: 10.1016/j.semcancer.2019.10.020. [Epub ahead of print].

364. Baselga J, Manikhas A, Cortés J, Lombart A, Roman L, Semiglazov VF, et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. *Ann Oncol*. (2014) 25:592–8. doi: 10.1093/annonc/mdt543

365. Park IH, Sohn JH, Kim SB, Lee KS, Chung JS, Lee SH, et al. An open-label, randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric micelle-formulated paclitaxel compared to conventional cremophor EL-based paclitaxel for recurrent or metastatic HER2-negative breast cancer. *Cancer Res Treat*. (2017) 49:569–77. doi: 10.4113/crj.2016.289

366. Bellblade U, Donprapaludi S, Konmineni N, Khan W. Liposomal formulations in clinical use: an updated review. *Pharmaceutics*. (2017) 9:12. doi: 10.3390/pharmaceutics9020012

367. Li Y, Humphries B, Yang C, Wang Z. Nanoparticle-mediated therapeutic agent delivery for treating metastatic breast cancer-challenges and opportunities. *Nanomaterials*. (2018) 8:361. doi: 10.3390/nano8060361

368. Fujiwara Y, Mukai H, Saeki T, Ro J, Lin YC, Nagai SE, et al. A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. *Br J Cancer*. (2019) 120:475–80. doi: 10.1038/s41416-019-0391-z

369. Kratz F, DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. *Expert Opin Invest Drugs*. (2007) 16:855–66. doi: 10.1517/13543784.16.8.855

370. Bellat V, Ting R, Southard TL, Vahdat L, Molina H, Fernandez J, et al. Functional peptide nanoparticles with unique tumor targeting and enzyme-induced local retention properties. *Adv Funct Mater*. (2018) 28:1803969. doi: 10.1002/adfm.201803969

371. Stokol T, Wan C, Blakey R, Bellat V, Law B. Aldoxorubicin-loaded nanoparticles are cytotoxic for canine mammary carcinoma and osteosarcoma cell lines in vitro: a short communication. *Res Vet Sci*. (2020) 128:86–9. doi: 10.1016/j.rvsc.2019.11.003

372. Núñez C, Estévez SV, Del Pilar Chantada M. Inorganic nanoparticles in treatment of breast cancer. *J Biol Inorg Chem*. (2018) 23:331–45. doi: 10.1007/s00775-018-1542-z

Effects of triple-negative breast cancer. *Breast Cancer Res Treat*. (2014) 148:489–99. doi: 10.1007/s10549-014-3180-7

Chaurasiya S, Yang A, Kang S, Lu J, Kim SI, Park AK, et al. Oncopvirus poxvirus CF33-NNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model. *Oncotarget*. (2020). 9:1729300. doi: 10.18632/oncotarget.4442

Gholami S, Marano A, Chen NG, Aguilar RJ, Frentzen A, Chen CH, et al. A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic
384. Silva A, Luis D, Santos S, Silva J, Mendo AS, Coito L, et al. Biological characterization of the antiproliferative potential of Co(II) and Sn(IV) coordination compounds in human cancer cell lines: a comparative proteomic approach. Drug Metabol Drug Interact. (2013) 28:167–76. doi: 10.1516/dmdi-2013-0015

385. Raposo LR, Roma-Rodrigues C, Jesus J, Martins LMDRS, Pomheiro AI, Baptista PV, et al. Targeting canine mammary tumours via gold nanoparticles functionalized with promising Co(II) and Zn(II) compounds. Vet Comp Oncol. (2017) 15:1537–42. doi: 10.1111/vco.12298

386. Efferth T, Miyachi H, Bartsch H. Pharmacogenomics of a traditional Japanese herbal medicine (Kampo) for cancer therapy. Cancer Genomics Proteomics. (2007) 4:81–91.

387. Zhu L, Li L, Li Y, Wang J, Wang Q. Chinese herbal medicine as an adjunctive therapy for breast cancer: a systematic review and meta-analysis. Evid Based Complement Alternat Med. (2016) 2016:9469276. doi: 10.1155/2016/1819794

388. Luo H, Vong CT, Chen H, Gao Y, Lyu P, Qiu L, et al. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. Chin Med. (2019) 14:48. doi: 10.1186/s13020-019-0270-9

389. Devassy JG, Nwachukwu ID, Jones PJ. Curcumin and cancer: barriers to obtaining a health claim. Nutr Rev. (2015) 73:155–65. doi: 10.1093/nutrit/nuu064

390. Holy J. Curcumin inhibits cell motility and alters microfilament organization and function in prostate cancer cells. Cell Motil Cytoskeleton. (2004) 58:253–68. doi: 10.1002/cm.20012

391. Walters DK, Muff R, Langsam B, Born W, Fuchs B. Cytoxic effects of curcumin on osteosarcoma cell lines. Invest New Drugs. (2008) 26:289–97. doi: 10.1007/s10637-007-9099-7

392. Tian B, Wang Z, Zhao Y, Wang D, Li Y, Ma L, et al. Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett. (2008) 264:299–308. doi: 10.1016/j.canlet.2008.01.041

393. Liu Q, Loo WT, Sze SC, Tong Y. Curcumin inhibits cell proliferation and migration of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFkappaB pathway. Phytomedicine. (2009) 16:916–22. doi: 10.1016/j.phymed.2009.04.008

394. Watson JL, Hill R, Yaffe PB, Greenshields A, Walsh M, Lee PW, et al. Curcumin causes superoxide anion production and p53-independent apoptosis in human colon cancer cells. Cancer Lett. (2010) 297:1–8. doi: 10.1016/j.canlet.2010.04.018

395. Yang CL, Ma YG, Xue YX, Liu YY, Xie H, Qiu GR. Curcumin induces small cell lung cancer NCI-H446 cell apoptosis via the reactive oxygen species-mediated mitochondrial pathway and the neocell death receptor pathway. DNA Cell Biol. (2012) 31:139–50. doi: 10.1089/dna.2011.13800

396. Hassan ZK, Daghestani MH. Curcumin effect on MMPs and TIMPs genes expression. Biofactors. (2013) 39:21–6. doi: 10.1002/biof.1080

397. Lynagh T, Lynch JW. Molecular mechanisms of Cys-loop ion channel receptor modulation by ivermectin. Front Mol Neurosci. (2012) 5:60. doi: 10.3389/fnmol.2012.00060

398. Dou Q, Chen HN, Wang K, Yuan K, Lei Y, Li K, et al. Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer. Cancer Res. (2016) 76:4547–69. doi: 10.1158/0008-5472.CAN-15-2887

399. Diao H, Cheng N, Zhao Y, Xu H, Dong H, Thamm DH, et al. Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling. BMC Vet Res. (2019) 15:276. doi: 10.1186/s12917-019-2026-2

400. Liu Y, Li W, Guo M, Li C, Qiu C. Protective role of selenium compounds on the proliferation, apoptosis, and angiogenesis of a canine breast cancer cell line. Biol Trace Element Res. (2016) 169:86–93. doi: 10.1007/s12011-015-0387-3

401. Li W, Guo M, Liu Y, Mu W, Deng G, Li C, et al. Selenium induces an anti-tumor effect via inhibiting intratumoral angiogenesis in a mouse model of transplanted canine mammary tumor cells. Biol Trace Element Res. (2016) 171:371–9. doi: 10.1007/s12011-015-0554-6

402. Zhou S, Wang F, Wong ET, Fonkem E, Hsieh TC, Wu JM, et al. Salinomycin: a novel anti-cancer agent with known anti-coccidial activities. Curr Med Chem. (2013) 20:4095–101. doi: 10.2174/15672050113109909199

403. Mai TT, Hamai A, Hienzsch A, Cañéque T, Müller S, Wincinski J, et al. Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat Chem. (2017) 9:1025–33. doi: 10.1038/nchem.2778

404. Kim KY, Park KI, Kim SH, Yu SN, Lee D, Kim YW, et al. Salinomycin induces reactive oxygen species and apoptosis in aggressive breast cancer cells as mediated with regulation of autophagy. Anticancer Res. (2017) 37:1747–58. doi: 10.21873/anticancer.11507

405. Li W, Yang H, Li X, Han L, Xu N, Shi A. Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer. Oncol Rep. (2019) 41:437–46. doi: 10.3892/or.2018.6805

406. Gao J, Liu J, Xie F, Lu Y, Yin C, Shen X. Co-delivery of docetaxel and salinomycin to target both breast cancer cells and stem cells by PLGA/TPGS nanoparticles. Int J Nanomed. (2019) 14:9199–216. doi: 10.2147/IJN.S201476

407. Tyagi M, Patro BS. Salinomycin reduces growth, proliferation and metastasis of cisplatin resistant breast cancer cells via NF-kappaB deregulation. Toxicol In Vitro. (2019) 66:125–33. doi: 10.1016/j.tiv.2019.05.004

408. Dewangan J, Srivastava S, Mishra S, Divakar A, Kumar S, Rath SK. Salinomycin inhibits breast cancer progression via targeting HIF-1a/VEGF mediated tumor angiogenesis in vitro and in vivo. Biochem Pharmacol. (2019) 164:326–35. doi: 10.1016/j.bcp.2019.04.026

409. Valdivia et al. Therapies in Canine Mammary Cancer

410. Rahman HS, Rasedee A, Yeap SK, Othman HH, Chartrand MS, Namvar F, et al. Biomodal properties of a natural dietary plant metabolite, zerumbone, in cancer therapy and chemoprevention trials. BioMed Res Int. (2014) 2014:920742. doi: 10.1155/2014/920742

411. Rahman HS, Rasedee A, How CW, Abdul AB, Zeenathsul NA, Othman HH, et al. Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and anti-tumic effect. Int J Nanomed. (2013) 8:2769–81. doi: 10.2147/ijn.s43513

412. Foong JN, Selvarajav GT, Rasedee A, Rahman HS, How CW, Beh CY, et al. Zerumbone-loaded nanostructured lipid carrier induces apoptosis of canine mammary adenocarcinoma cells. BioMed Res Int. (2018) 2018:8691569. doi: 10.1155/2018/8691569

413. Señifab R, Mortazavi P, Hosseini S. Antiproliferative effect of berberine on canine mammary gland cancer cell culture. Biomed Rep. (2017) 6:955–60. doi: 10.3892/br.2016.809

414. Weinstein M, Lessard J, Pressman R, Meek J, Dvash M, Oppenheimer M, et al. The triple-negative breast cancer cell line MDA-MB-231 is specifically inhibited by the ionophore salinomycin. Anticancer Res. (2019) 39:2821–7. doi: 10.21873/anticancer.13410
419. Versini A, Colombeau L, Hienzsch A, Gaillet C, Retailleau P, Debieu S, et al. Salinomycin derivatives kill breast cancer stem cells by lysosomal iron targeting. Chemistry. (2020) 26:7416–24. doi: 10.1002/chem.202000335

420. Naujokat C, Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. (2012) 2012:950658. doi: 10.1155/2012/950658

421. Du H, Zhou B, Zhang H, Jin Y, Zhang D, Lin D. Salinomycin inhibits canine mammary carcinoma in vitro by targeting cancer stem cells. Oncol Lett. (2017) 14:427–32. doi: 10.3892/ol.2017.6164

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.